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ABSTRACT: 
Title: Diagnostic accuracy of Acoustic Radiation Force Impulse (ARFI) Elastography of liver and 
spleen to identify Noncirrhotic portal fibrosis (NCPF) from cirrhosis with portal hypertension and 
comparison with liver biopsy. 
Aims and objectives: The primary aim is to assess the diagnostic accuracy of ARFI 
elastography of liver and spleen to identify patients with NCPF / Non cirrhotic intrahepatic 
portal hypertension (NCIPH) from cirrhosis with portal hypertension as compared to liver 
biopsy.  
To assess the diagnostic accuracy of ARFI elastography of liver and spleen to differentiate 
significant liver fibrosis from non-significant liver fibrosis in patients with portal 
hypertension and to predict clinically significant portal hypertension (CSPH) as compared to 
Hepatic venous pressure gradient (HVPG) and the presence high risk esophageal varices 
(EV) on endoscopy.  
Methods:  
Prospective study approved by IRB. Total 58 patients were studied. Patients with pre-biopsy 
preliminary diagnosis of cryptogenic cirrhosis were included and underwent ARFI 
elastography of the liver and the spleen. The liver stiffness (LS), spleen stiffness (SS), spleen 
stiffness to liver stiffness ratio (SS/LS) velocity measurements were correlated with the 
grades of liver fibrosis on biopsy, clinical and biochemical parameters, HVPG and the 
presence of high risk varices on endoscopy. Patients with other causes of portal hypertension 
were also studied who did not undergo liver biopsy. 
 
 
Results:  
48 cases with preliminary diagnosis of cryptogenic cirrhosis were studied. 39 cases had liver 
biopsy. 11 cases (28%) were proven to be NCPF on biopsy. The rest of the 28 cases were 
autoimmune chronic liver disease, cryptogenic cirrhosis, Wilson‟s disease, drug induced 
hepatitis, Non alcoholic fatty liver disease, Thalassemia and HBV related chronic liver 
disease. 9 cases were clinically suspected to have NCPF who did not undergo liver biopsy 
were also studied.  
58 cases of portal hypertension of any etiology were studied to assess the correlation of ARFI 
of the liver and the spleen with the presence of high risk esophageal varices on endoscopy. 
This group includes 39 liver biopsy cases, 9 suspected NCPF cases without liver biopsy and 
10 cases of portal hypertension due to other known etiologies. 
LS had 36% sensitivity, 93% specificity, PPV of 90%, NPV of 78.8% and kappa of 0.28 and 
p value of 0.04 to identify NCPF from other liver cirrhosis which was statistically significant. 
SS had 70% sensitivity, 20% specificity, PPV of 26.9% and NPV of 62.5%, kappa of -0.63 
and p value of 0.5 which was not statistically significant. The SS/ LS ratio had 70% 
sensitivity, 79.2% specificity, PPV of 58.3%, NPV of 86.4% with kappa of 0.46 and p value 
of 0.06 which was statistically not significant. The combination of either LS, SS or SS/ LS 
had sensitivity of 82%, specificity of 21.4 %, PPV of 29%, NPV of 75% and kappa of 0.02 
(p=0.8).The best ARFI elastography parameter to identify NCPF from other causes of 
cirrhosis was found to be SS/LS with good sensitivity, specificity, negative predictive value 
and good kappa correlation.  
LS, product of LS and SS and ratio of SS/ LS were found to statistically significant 
differentiate between significant from non-significant liver fibrosis. Spearman correlation 
(rho) of the liver stiffness (LS) with the fibrosis grades on liver biopsy was 0.54 with p value 
of < 0.001 which was statistically significant. 
Both LS and SS were found to have low sensitivity with low kappa agreement and were 
statistically not significant to identify clinically significant portal hypertension as compared 
to HVPG. 
 
Conclusions: ARFI elastography of the liver and the spleen in combination have good 
sensitivity to identify NCPF from cirrhosis with portal hypertension as compared to liver 
biopsy. The best elastography parameter was the spleen stiffness to liver stiffness ratio.  Liver 
and spleen stiffness independently are not adequate. LS and the SS/LS have good sensitivity 
to identify significant liver fibrosis as compared to liver biopsy. There is good correlation 
with liver stiffness velocities and grades of liver fibrosis. ARFI of the liver and spleen have 
low sensitivity and low specificity to identify CSPH as compared to HVPG and the presence 
of high risk EV on endoscopy. 
 
 
 
 
 
 
 
 
         AIMS AND OBJECTIVES: 
 
• Primary aim is to assess the diagnostic accuracy of Acoustic radiation force impulse 
(ARFI) elastography of liver and spleen to identify Noncirrhotic portal fibrosis 
(NCPF)/ Noncirrhotic portal hypertension (NCIPH) from cirrhosis with portal 
hypertension as compared to liver biopsy in patients with portal hypertension. 
• To assess the diagnostic accuracy of ARFI elastography of liver and spleen to 
differentiate significant liver fibrosis from non-significant liver fibrosis.  
• To assess the diagnostic accuracy of ARFI elastography of liver and spleen to predict 
clinically significant portal hypertension (CSPH) as compared to Hepatic venous 
pressure gradient (HVPG) and the presence high risk esophageal varices on 
endoscopy. 
 
 
 
 
 
 
 
 
 
 
 
         
JUSTIFICATION OF THE STUDY: 
Patients with portal hypertension, in whom no cause for liver disease is found, are often 
labelled as cryptogenic cirrhosis. Occult hepatitis B infection, end-stage non alcoholic 
fatty liver disease and autoimmune liver disease are potential causes of cryptogenic 
cirrhosis in India.  
Noncirrhotic portal fibrosis (NCPF) / Noncirrhotic intrahepatic portal hypertension 
(NCIPH) is a disease which is seen more commonly in Indians and Japanese as 
compared to the west. It is difficult to diagnose NCPF on routine USG and Doppler as 
imaging characteristics mimic cryptogenic cirrhosis and therefore is commonly 
misdiagnosed as cirrhosis on imaging. However, these patients do not have features of 
cirrhosis on histopathology and majority do not progress into liver cell failure. The main 
morbidity in NCPF portal hypertension causing variceal bleed, which when adequately 
treated, most of these patients have an excellent prognosis.  Hence, there is a need to 
accurately diagnose NCPF from other causes of cryptogenic cirrhosis and monitor the 
progression of disease in these patients. 
The gold standard method for detecting the presence of liver fibrosis and the degree of 
fibrosis is by liver biopsy which is an invasive procedure with known complications and 
limitations. In the recent past, ARFI elastography of the liver has emerged as a novel 
ultrasound based modality to non-invasively predict fibrosis of liver and spleen. There 
are studies which have used ARFI elastography of the liver and the spleen for viral 
hepatitis and have shown good correlation of elastography velocity score with the grades 
of liver fibrosis on biopsy. Studies have shown that upto 40% of patients with a 
preliminary diagnosis of cryptogenic cirrhosis who undergo liver biopsy are NCPF.  
ARFI elastography has been studied in patients with portal hypertension. To our 
knowledge after literature review, only one published study is reported in literature about 
the use of ARFI elastography in of liver and spleen to diagnose NCPF.  There are no 
Indian studies regarding the use of ARFI elastography to predict NCPF. Hence this study 
aims at assessing the diagnostic accuracy of ARFI elastography of liver and spleen to 
identify NCPF in Indian population from patients with other causes of cirrhosis as 
compared to liver biopsy which is the gold standard.  
In future, we hope ARFI elastography can be used as a non invasive predictor of NCPF, 
and is included as one of the diagnostic criterion for non-invasive diagnosis and follow 
up of NCPF and thereby reduce the need for liver biopsy. 
Clinically significant portal hypertension (CSPH) is the main cause of morbidity in 
patients with chronic liver disease. The gold standard to diagnose CSPH is hepatic 
venous pressure gradient (HVPG) which is an invasive procedure. This study also aims 
at studying the diagnostic accuracy of ARFI elastography of the liver and spleen to 
predict CSPH as compared to HVPG and the presence of high risk esophageal varices on 
endoscopy.  
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INTRODUCTION TO PORTAL HYPERTENSION: 
Portal hypertension is a common and unavoidable sequel of cirrhosis in patients with chronic 
liver disease. The relevance of portal hypertension is due to the frequency and severity of its 
complications which is the main cause for hospital admission, mortality and liver 
transplantation. Portal hypertension (PH) is due to sustained increase in pressure in the portal 
venous system. The normal portal pressure is expressed as portal venous pressure gradient. It 
is the difference between the absolute pressure in the portal venous system and the intra-
abdominal systemic venous pressure (IVC) and represents the perfusion pressure of the liver 
with the portal blood. Elevated portal pressure leads to splenomegaly, development of porto-
systemic collaterals which shunt the portal blood bypassing the liver into the systemic 
circulation and a hyperkinetic circulation. Normal portal pressure gradient (PPG) is 1-5 mm 
of Hg. Clinically significant portal hypertension which is associated with various 
complications is when the PPG exceeds 10 mm of Hg. Subclinical portal hypertension is 
when the PPG is between 5-9 mm of Hg.(1) 
NATURAL HISTORY OF PORTAL HYPERTENSION:  
Among asymptomatic patients with cirrhosis 80- 90% have elevated PPG which is clinically 
measured as elevated hepatic venous pressure gradient (HVPG) and 40 % of these patients 
have esophageal varices on endoscopy. The esophageal varices develop at the rate of 6% per 
year among the patient‟s asymptomatic patients without varices and about 10% per year in 
patients with HVPG> 10 mm of Hg. 10- 30% of patients with untreated esophageal varices 
bleed within 2 years. The incidence of variceal bleed increases with the size of varices, 
presence of red colour signs on endoscopy and the degree of liver cell failure. These patients 
have 6- 20% mortality during the episode of variceal bleed and two thirds of the patients can 
rebleed within 2 years.  Current medical treatments reduced the risk of first variceal bleed and 
rebleed rate by 50% (2). 
PATHOPHYSIOLOGY OF PORTAL HYPERTENSION: 
The portal venous system is unique unlike other venous systems in the body. It is the main 
vascular supply to the liver, making the liver the organ to receive maximum blood flow. 
Changes in hepatic resistance results in marked circulatory changes in the rest of the body. 
Portal hypertension is initiated by an increased resistance to portal blood flow and is 
exacerbated by and increased portal collateral blood flow (3). The most common cause of 
increased portal blood flow resistance is chronic liver disease, the next common being hepatic 
schistosomiasis. Other less common causes are extra hepatic portal vein occlusion and 
idiopathic non cirrhotic portal hypertension which account for approximately 10 % (2). There 
are two main mechanisms causing increase in hepatic vascular resistance; the structural and 
the dynamic component. The structural component is due to distortion of liver architecture by 
fibrosis, nodule formation, angiogenesis and vascular occlusion. The dynamic component is 
due to increased vascular tone by the activated hepatic stellate cells and myofibroblasts 
around the sinusoids, in the fibrous septa and in the smooth muscle cells in the hepatic 
vasculature. The dynamic component represents liver vascular dysfunction accounting for 
30% of the increase in hepatic resistance. There is also increase in the vasoconstrictors and 
decrease in vasodilators. In the advanced stage of portal hypertension, there is increase 
splanchnic blood flow in the portal collaterals. This is due to splanchnic arteriolar 
vasodilatation and neoangiogenesis due to increase in vasodilators like VGEF, nitric oxide. 
Due to splanchnic vasodilatation there is systemic hypotension, vascular under filling, 
activation of endogenous vasoactive system, plasma volume expansion and increase in 
cardiac index, leading to hyperkinetic syndrome which leads to ascites and renal dysfunction 
in cirrhosis.  Formation of porto-systemic collaterals and varices are due to opening of pre-
existing communicating vessels between the portal and the systemic circulation and 
angiogenesis (4).  
 CLASSIFICATION OF PORTAL HYPERTENSION: 
Any disease which causes interruption of blood flow between the spleen and the right atrium 
can cause portal hypertension. Portal hypertension is divided into prehepatic, hepatic and post 
hepatic portal hypertension.   
The prehepatic portal hypertension group involves the spleno-portal mesenteric axis and have 
normal wedged hepatic venous pressure (WHVP), free hepatic venous pressure (FHVP) and 
normal hepatic venous pressure gradient (HVPG). The common causes are caused portal vein 
thrombosis, splenic vein thrombosis, congestive splenomegaly (Banti‟s syndrome) and 
arterio-venous fistulae. The intrahepatic portal hypertension group have increased wedged 
hepatic venous pressure (WHVP), normal free hepatic venous pressure (FHVP) and increased 
hepatic venous pressure gradient (HVPG). They are further subdivided into presinisoidal, 
sinusoidal and post sinusoidal causes of hepatic portal hypertension. The presinisoidal causes 
are Non-cirrhotic portal fibrosis (NCPF), schistosomiasis, and congenital hepatic fibrosis. 
The sinusoidal portal hypertension is seen in cirrhosis due to various etiologies, Alcoholic 
hepatitis, nodular regenerative hyperplasia and polycystic liver disease. The post sinusoidal 
causes are sinusoidal obstructive syndrome and Budd- Chiari syndrome. The post hepatic 
portal hypertension group have increased wedged hepatic venous pressure (WHVP) and free 
hepatic venous pressure (FHVP) and normal hepatic venous pressure gradient (HVPG). 
Common causes of post hepatic portal hypertension are Budd Chiari syndrome, cardiac 
causes like congestive cardiac failure, constrictive pericarditis and restrictive cardiomyopathy 
and pulmonary hypertension (5). 
 
 
INCIDENCE PORTAL HYPERTENSION: 
The most common cause of portal hypertension in the western countries is cirrhosis.  Non 
cirrhotic portal hypertension accounts for 10 % of the cases of portal hypertension (2). 
Studies in various other countries have found that hepatitis C and alcohol related liver disease 
are the main causes of portal hypertension, however the scenario in India differs from the 
rest. In India, few studies are reported in literature studying the various etiologies of portal 
hypertension.  One of the largest studies is by Goel et al. who studied the spectrum of various 
etiologies of portal hypertension among adults at a tertiary care centre in South India. They 
have studied a total of 583 patients with portal hypertension. Based on non-invasive methods, 
they have found that the commonest cause of portal hypertension as cryptogenic 
cirrhosis(35%), the next common causes being chronic liver disease due to alcohol 
consumption (29%), chronic viral hepatitis like hepatitis B( 17%) and hepatitis C as (9%). Of 
the patients with cryptogenic cirrhosis who underwent liver biopsy for further evaluation, 
41% were found to be non-cirrhotic portal hypertension (NCIPH), and 5 patients had non 
alcoholic fatty liver disease. The vascular disorders causing portal hypertension were found 
to be 10%. 
In the future, due to increase in sedentary lifestyle, better standards of living and metabolic 
syndrome, there in an expected increase in the patients with non-alcoholic fatty liver disease 
(NAFLD) and cirrhosis related to alcohol consumption. With increase in various awareness 
programmes, there seems to be a decline in the incidence of chronic viral hepatitis causing 
portal hypertension. In India, among children, for reasons yet unclear, the vascular causes 
like extra-hepatic portal vein obstruction is the commonest cause of portal hypertension, the 
others being non- cirrhotic portal hypertension and Wilson‟s disease (6). 
 
 NONCIRRHOTIC PORTAL FIBROSIS (NCPF) / NONCIRRHOTIC 
INTRAHEPATIC PORTAL HYPERTENSION (NCIPH): 
Noncirrhotic portal fibrosis (NCPF) /Non cirrhotic intrahepatic portal hypertension (NCIPH) 
is a group of disorder characterized by elevated portal pressure due to intrahepatic or 
prehepatic pathologies in the absence of cirrhosis. Non cirrhotic portal fibrosis (NCPF) is one 
of the important causes of non cirrhotic portal hypertension among Asians. Other 
terminologies for the same condition are non cirrhotic intrahepatic portal hypertension (7), 
Idiopathic non cirrhotic portal hypertension and hepato-portal sclerosis. The Asian Pacific 
Association for Study of Liver (APASL), working party on portal hypertension defined as, 
“NCPF/ IPH is a disease of uncertain etiology characterized by periportal fibrosis and 
involvement of small and medium branches of the portal vein, resulting in the development 
of portal hypertension. The liver functions and structure primarily remain normal. 
 EPIDEMIOLOGY OF NCPF: 
NCPF is more common in the developing countries rather than the developed countries. It is 
more common among people from low socio- economic strata. In India initial studies in 
1980s showed the incidence of 23%; however recent studies show a decline in the incidence.  
NCPF is more commonly seen in young adults in the third and the fourth decade of life and 
has no sex predilection (8). 
 ETIOPATHOGENESIS OF NCPF: 
There is limited insight regarding the etiopathogenesis of NCPF and has various proposed 
hypothesis to explain this heterogenous group of disease. There is varied degree of injury of 
predominantly presinisoidal region of the portal venous system. The factors which have been 
associated to cause the portal venous injury are infections, xenobiotics exposure and various 
immunological abnormalities. Repeated intestinal infection causes intramural thrombus 
formation and activation of stellate cells which leads to presinisoidal fibrosis. Arsenic 
induced hepatic fibrosis was found to be related to IL-6 and TNF- alpha which cause hepatic 
oxidative stress.  Abnormalities of T- cells and adhesion molecules have been found, but the 
exact role in the pathogenesis is not clearly understood. Other association of NCPF are portal 
or umbilical pyemia, autoimmune disorders, prothrombotic states, toxins like chronic vinyl 
alcohol exposure, copper sulphate, prolonged treatment with methotrexate, 6- 
mercaptopurine, azathioprine and hypervitaminosis A. In majority of the cases, the exact 
cause remains unknown (8). 
CLINICAL FEATURES OF NCPF: 
Among patients with portal hypertension NCPF is an important cause of upper 
gastrointestinal bleed, constituting about 15% of cases. The variceal bleed is well tolerated in 
these patients. They commonly present with left upper quadrant mass (splenomegaly) or iron 
deficiency anaemia. Jaundice, ascites and edema are uncommon. The signs of liver cell 
failure like palmar erythema, parotid enlargement, spider angioma, testicular atrophy and 
gynaecomastia are rare (8). 
LAB TESTS IN NCPF: 
Liver function tests are usually normal in NCPF.  Hypersplenism can cause pancytopenia 
with normochromic normocytic anaemia, leucopenia and thrombocytopenia. Microcytic 
hypochromic anaemia in these patients is due to gastrointestinal blood loss. Bone marrow 
examination shows hypercellular marrow. NCPF patients can have coagulation abnormalities 
with significantly increased international normalized ratio (INR), decrease in fibrinogen and 
platelet aggregation due to endotoxemia or porto-systemic collaterals. Esophageal varices are 
seen in majority of patients (85-90%) and are of often high grade at the time of diagnosis. 
Gastric varices are seen in 25% of patients and portal hypertensive gastropathy is uncommon 
in NCPF as compared to cirrhotic patients. Anorectal varices are commonly seen in NCPF. 
Since the site of resistance within the liver is presinisoidal, the hepatic venous pressure 
gradient is normal or near normal (8). 
HISTOPATHOLOGY OF NCPF: 
The gross examination of liver in NCPF may be normal, enlarged or even shrunken. The liver 
surface may be smooth or nodular like cirrhosis with thickening of the capsule; however the 
deeper parenchyma is grossly normal.  There is sclerosis of small and medium sized portal 
vein branches with increase in portal collagenous connective tissue and obliteration of small 
branches of portal vein.  Hence histological hallmark of NCPF is termed as „Obliterative 
portal venopathy‟. Occasionally recanalized thrombi are seen. Liver needle biopsy shows 
small portal vein obliteration, aberrant vasculature, portal tract fibrosis and absence of 
regenerative nodules or features of cirrhosis (8). 
DIAGNOSIS OF NCPF: 
The diagnosis is relatively easy; however it is important to differentiate NCPF from Child A 
cirrhosis and extra-hepatic portal vein obstruction. The diagnostic features of NCPF include 
moderate to massive splenomegaly, portal hypertension represented as varices and or 
collaterals, absence of signs of chronic liver cell failure, patent spleno-portal axis and hepatic 
veins on ultrasound and doppler, normal or near normal liver function tests, absence of serum 
markers for hepatitis B and C infection, no known etiology for liver disease, normal or near 
normal hepatic venous pressure gradient (HVPG), no evidence of cirrhosis or parenchymal 
injury on histopathology, no decompensation after variceal bleed except transient ascites and 
on imaging dilated and thickened portal vein with peripheral pruning and periportal 
hyperechoic areas (3%) (8).  
NATURAL HISTORY AND PROGNOSIS OF NCPF: 
Unlike cirrhosis, NCPF is usually non-progressive and has good prognosis especially if the 
portal pressures are reduced by shunt surgery or other procedures.  Recently, due to increase 
in orthotopic liver transplantation, it has been shown that native explants livers which were 
initially labelled as cryptogenic cirrhosis was subsequently diagnosed as NCPF. Hence NCPF 
can progress to end stage liver disease requiring liver transplantation (9).  NCPF has excellent 
prognosis. The major cause of mortality is acute gastrointestinal bleed which is significantly 
lower than cirrhotic patients. Hence after successful treatment of esophagogastric varices, the 
survival is excellent. Selective shunt surgery can be done in NCPF; however the morbidity 
can be increased due to shunt occlusion or post shunt encephalopathy (8). 
MANAGEMENT OF NCPF: 
The management of patients with NCPF is to prevent active bleeding and to provide primary 
and secondary prophylaxis. Acute variceal bleed is controlled endoscopic therapy with band 
ligation and vasoactive drugs to decrease portal pressure.  If the endoscopic therapy fails after 
2 procedures then the alternative treatment options include surgery or transjugular 
intrahepatic porto-systemic shunt (TIPS). Primary prophylaxis for variceal bleed includes 
endoscopic variceal band ligation (EVL) or beta blockers. Shunt surgery in NCPF patients for 
primary prophylaxis of large esophageal varices can be done if the patient has large 
splenomegaly with very low platelet count (<20,000),  stays far away from a medical centre 
where a upper gastrointestinal bleed can be managed and has a rare blood group. The 
secondary prophylaxis includes EVL or decompressive surgery, the former is preferred. 
Newer therapies like image guided interventions can be used to prevent variceal bleed. These 
include partial spleen embolization, Balloon-occluded retrograde transvenous obliteration 
(BORTO), percutaneous transhepatic obliteration (PTO) and TIPS (8). 
 NON INVASIVE METHODS TO ASSESS LIVER FIBROSIS: 
The gold standard to asses liver fibrosis is liver biopsy with histopathological examination. 
However, liver biopsy has many limitations. It is an invasive procedure with known 
complications and mortality. Sampling error can occur with liver biopsy as the liver fibrosis 
is not uniform in the liver and only 1/ 50,000 th part of the liver is examined. Thus, liver 
biopsy can underestimate the degree and extent of fibrosis. There are known interobserver 
variations in reporting liver fibrosis. Liver biopsy specimen can get fragmented or sample 
may be inadequate. Hence, due to the limitations of liver biopsy, there is an increased need to 
non invasively diagnose, monitor patients with chronic disease with various degrees of liver 
fibrosis and also assess the treatment response. The non invasive methods reduce the need for 
liver biopsy, can predict the complications of portal hypertension and thereby are cost 
effective and reduce the need for invasive methods and the morbidity associated with those 
procedures. The various non invasive tests to assess liver fibrosis are elastography and serum 
fibrosis markers. They have been mostly studied in patients with chronic hepatitis C and 
hepatitis B.  
 
ULTRASOUND ELASTOGRAPHY -NON INVASIVE TOOL TO ASSESS FIBROSIS: 
Since ancient times one of the key method of detecting and characterizing pathologies is by 
assessment of tissue stiffness by palpation. In the recent times, ultrasound elastography has 
evolved as an imaging tool to assess tissue stiffness or elasticity which is clinically assessed 
by palpation. Elastography is the imaging technique used to assess tissue elasticity. It induces 
shear stress in the tissues by creating low frequency vibrations, analyses the resultant stress 
and quantifies tissue stiffness. Tissue stiffness is measured by Young‟s modulus which 
quantifies tissue stiffness and is expressed as kilopascals (kPa).  Young‟s modulus or 
Elasticity (E) is defined as the ratio between applied stress and induced strain. E=s/e, where 
E- elasticity, s-externally applied stress and e- induced strain. The normal elastography values 
of various tissues in the body have been defined and theses values differ in various 
pathological states. They are two types of externally applied mechanically induced waves by 
ultrasound. They are compression or bulk waves and shear waves. Compression waves 
traverse at a high velocity through the tissues (1500 cm/ sec) by compressing tissue layers 
and the reflected compressional wave echoes are analysed. Shear waves traverse slower (1 to 
10 cm/ sec) though the tissues and propagate by tangential or sliding force between the tissue 
layers.  
TYPES OF ELASTOGRAPHY: 
They are three types of elastography; static, dynamic and shear wave based elastography. In 
static elastography, uniform compression of the tissue is obtained by external compression by 
the user on the body surface, and the deformation of the tissues is calculated and represented 
as an elastogram by the ultrasound machine. The tissues which are less deformed as 
represented as darker areas on elastogram. It is not a quantitative method to assess tissue 
stiffness, as the amount of externally applied force is unknown and hence Young‟s modulus 
cannot be reconstructed. Dynamic elastography uses continuous monochromatic vibrations to 
assess tissue elasticity.  It is a quantitative method used in MR systems. Shear wave 
elastography is a quantitative method of assessing tissue stiffness where the external 
compression force is produced by the ultrasound transducer. The acoustic radiation force 
induced ultrasound beam pushes the tissues in the direction of propagation and the displaced 
mechanical waves in the human tissues is measured. Elasticity image is represented as a 
colour coded image superimposed on B mode gray scale image. Colour scale is quantitative 
as stiffer tissues are represented as red and softer tissues are represented as blue which 
correspond to the scale as kPa. The image resolution is 1mm and the elastography image is 
refreshed in real time. The imaging frame rate corresponds to the acoustic output as per 
international standards.  
TRANSIENT ELASTOGRAPHY (TE-FibroScan): 
Transient elastography (FibroScan) is a non-invasive, rapid and reproducible ultrasound 
based method for assessing liver stiffness. It was developed by Echosens, based on the 
principle of Hooke‟s law, which demonstrates the material strain response to external stress. 
FibroScan has an ultrasound transducer probe which is mounted on the axis of a vibrator. 
This transmits low frequency vibrations which produce elastic shear waves in the liver. Pulse-
echo ultrasound acquisition is used which measures the wave propagation velocity which is 
proportional to the tissue stiffness. The stiffer tissues have faster wave propagation velocities.  
 
Liver fibrosis using transient elastography has been well studied as a non invasive tool to 
assess fibrosis. In TE the liver stiffness measurements are performed from the right lobe of 
the liver with the patient in the dorsal decubitus position with maximum abduction of the 
right arm. Using A- mode ultrasound images a portion of liver is selected between 25 mm 
and 65 mm below the skin surface free of liver vasculature. Ten measurements are obtained 
and for reliable measurements the success rate of 60% and interquartile range of less than 
30% of the median liver stiffness measurement is suggested. The median value is taken as 
representative and is expressed as kPa. (10). The cut off value to differentiate liver fibrosis 
and cirrhosis is13 kPa and to differentiate between fibrosis and no significant fibrosis is 7.6 
kPa has been suggested (11).  
 
Nierhoff et al, compared meta-analysis of transient elastography TE and found that the 
overall diagnostic accuracies of 0.94 for the diagnosis of liver cirrhosis, 0.89 for the diagnosis 
of severe fibrosis and 0.84 for the diagnosis of significant fibrosis, respectively (12).  
ACOUSTIC RADIATION FORCE IMPULSE ELASTOGRAPHY (ARFI): 
PRINCIPLE: 
Acoustic radiation force impulse (ARFI) elastography is a radiation force based imaging 
method combined with conventional B mode ultrasound (Acuson S 2000, SEIMENS Medical 
Solutions). The „Virtual Touch Tissue Quantification‟ (VTQ) provided by SEIMENS 
quantifies the tissue stiffness by shear wave velocity of acoustic radiation force impulse 
displacement within the human tissues. It is represented as m/sec and is proportional to the 
square root of the tissue elasticity (13).  
To obtain a baseline signal, an initial ultrasonic pulse at diagnostic intensity level is 
transmitted by the transducer. Subsequently, a short duration (0.3 s) high intensity acoustic 
„pushing pulse‟ is applied by the transducer, followed by a series of diagnostic intensity 
pulses.  The diagnostic pulses are used to track the displacement of the tissues caused by the 
pushing pulse. The response of the tissues to the radiation force is assessed by conventional 
B-mode imaging pulses, and are represented shear wave velocity measurements as m/ sec. 
PROTOCOL FOR ARFI ELASTOGRAPHY OF LIVER: 
ARFI elastography Virtual Touch Tissue Quantification imaging is performed with curved 
array 4 MHz, B-mode ultrasound transducer. The anatomic region of interest is analysed 
using a „region of interest‟ (ROI) cursor measuring 10 by 5 mm simultaneously with real time 
B- mode imaging. The patient lies in the dorsal decubitus position with the right arm 
maximally abducted. The right lobe of the liver is assessed through the intercostal approach.  
The other approach is the abdominal approach; the intercostal approach has been found to be 
superior to the abdominal approach (13). 
 
 
 PLACEMENT OF REGION OF INTEREST (ROI) IN THE LIVER USING ARFI 
ELASTOGRAPHY: 
According to Goertz et al, who evaluated 57 patients, the best ARFI measurements with 
lowest rate of invalid measurements were using the intercostal approach to segments VII/ 
VIII of the liver (14). In a study done by Bota et al. among 83 patients in segments V and 
VIII of liver, there was no significant statistical difference between the mean liver stiffness 
between the two segments. They also found that the correlation between ARFI and fibrosis 
was similar in segments 5 and 8 of liver (r=0.836 vs. r=0.784) (p=0.33). There was no 
significant difference between the mean liver stiffness values between right and left lobe of 
the liver (2.06±0.1 vs.2.08±0.98 m/s, p=0.89) (15).  The analysis of the right lobe was found 
to produce consistent values. The left lobe measurements have been found to have outliers, 
probably due to the interference of the shear wave by the cardiac pulsations. The ROI is 
placed 2-3 cm from the surface of the liver for accurate assessment, not exceeding a depth of 
5 cm (13). There is no definite consensus on the depth of the ROI from the liver surface.  
Short duration acoustic pulses with a fixed transmitted frequency of 2.6 MHz is used to 
mechanically excite and cause localised displacement of the tissues within the ROI. The 
tissue displacements create a shear wave propagation which is away from the region of 
excitation. The ultrasound beam tracking laterally to the single push beam is estimated as the 
maximum displacement. The shear wave speed can be reconstructed by measuring the time to 
peak displacement at each lateral location (16). The propagation velocity within the tissue is 
proportional to the square root of tissue elasticity. The result is expressed in meters per 
second (range, 0.5–4.4 m/s with±20 % accuracy over the range).  
While taking the ARFI measurements, the patient is asked to stop breathing momentarily. 
Minimum of 10 measurements are taken from the liver and the median value is calculated. A 
good quality assessment includes IQR less than 30 % and success rate greater than 60% (17). 
DIAGNOSTIC ACCURACY OF ARFI ELASTOGRAPHY IN STAGING LIVER 
FIBROSIS: 
Nierhoff et al, performed systematic literature review of 36 articles and 3,951 patients 
evaluating the diagnostic accuracy of ARFI in staging liver fibrosis. Meta-analysis of the area 
under the receiver operating characteristic (ROC) curve (AUROC) and the diagnostic odds 
ratio (DOR) were performed. The inclusion criteria were all the studies which evaluated the 
efficacy of ARFI elastography of liver with liver biopsy as reference standard, METAVIR 
scoring system for liver fibrosis staging on biopsy, assessment of AUROC for fibrosis stage 
F>_2, F>_ 3, F=4 according to METAVIR or comparable liver fibrosis scoring system,  and 
all the studies which studied the sensitivity, specificity, positive predictive value, negative 
predictive value according to the various ARFI shear wave velocity cut off values for various 
stage of liver fibrosis on biopsy. 
 
A diagnostic tool is defined as perfect if the AUROC is 1, excellent if the AUROC is greater 
than 0.9 and good if the AUROC is greater than 0.8. The mean diagnostic accuracy of ARFI 
expressed as the AUROC was 0.84 for the diagnosis of significant fibrosis (F≥2), 0.89 for the 
diagnosis of severe fibrosis (F≥3) and 0.91 for the diagnosis of liver cirrhosis (F=4). 
The studies which included HBV infected patients, the overall AUROC 0.87 (95 % CI, 0.85–
0.90) and for studies without HBV-infected patients it was 0.92 (95 % CI, 0.89–0.95). There 
was significant influence on AUROC for F>_2 by mean BMI. It was found that with increase 
in BMI, there was significant decrease in the AUROC (P=0.0062) Hence, ARFI elastography 
of the liver has a good diagnostic accuracy for detecting significant liver fibrosis (F >_2, 
F>_3) and excellent for liver cirrhosis (F=4) (18). 
 
 
REPRODUCIBILITY OF ARFI: 
Since ARFI is real time ultrasound based quantitative measurement of tissue stiffness, 
interobserver variability has been studied. According to Boursier et al, the interobserver 
variability of ARFI is excellent with interclass correlation of 0.91 (19).   Friedich Rust et al, 
found that there was 87% agreement between two observers regarding ARFI derived 
elastography stages (20).  
 
ARFI ELASTOGRAPHY SHEAR WAVE VELOCITY (SWV) VALUES OF LIVER 
IN NORMAL HEALTHY SUBJECTS AND ITS CORRELATION WITH 
DIFFERENT STAGES OF FIBROSIS ON LIVER BIOPSY: 
Several studies have been done by among healthy volunteers to determine the normal liver 
stiffness values by ARFI elastography.  
Study done by Popescu et al. found the mean shear wave velocity of liver as 1.15 ± 0.21 m/s. 
Hoster et al. studied 68 healthy volunteers and have found the mean wave velocity of liver as 
1.19 m/ sec.  In another study done by Kim et al. among 133 healthy volunteers, that the 
mean shear wave velocity to be 1.08 ± 0.15 m/s (10).  
A large study done by Kirches at al. in which the normal values and the shear wave velocity 
values of significant fibrosis and cirrhosis of liver was obtained with ARFI elastography 
using transient elastography  (FibroScan- FS) as reference standard. The study enrolled six 
hundred and sixty six patients and sixty eight patients underwent liver biopsy. In this study 
they have found that the there was significant success rate of ARFI of liver as compared to 
FS [604/606 (99.7%) vs 482/606 (79.5%), P < 0.001].  There was significant correlation 
between ARFI-SWV and FibroScan liver stiffness (FS-LS) (r = 0.920, P < 0.001). As the 
stage of fibrosis increased, there was significant increase in the ARFI-SWV. For patients with 
no significant liver fibrosis, ARFI-SWV was found to be 1.09 ± 0.13 m/s and with FS-LS < 
7.6 kPa); for patients with significant liver fibrosis as 1.46 ± 0.27 m/s (FS-LS ≤ 13.0 kPa); 
and for patients with liver cirrhosis as 2.55 ± 0.77 m/s (FS-LS > 13.0 kPa). Thus, according 
to Kirches at al. ARFI-SWV cut-off values of liver with no significant fibrosis was found to 
be (1.29 m/s; sensitivity, 91.4% and specificity 92.6%) and for liver cirrhosis (1.60 m/s; 
sensitivity, 92.3% and specificity 96.5%).  The optimal cut-off ARFI shear wave velocity 
measurement for predicting liver fibrosis (F ≥ 2) was 1.32 m/s (sensitivity 87.0% and 
specificity 80.0%) and for liver cirrhosis (F4) 1.62 m/s (sensitivity 100% and specificity 
85.7%), among the patients who underwent liver biopsy.  There was excellent inter-and 
intraobserver reproducibility for ARFI-SWV determinations (10). 
According to a large meta-analysis by Nierhoff et al, the ARFI shear wave velocity cut-off 
values of liver are 1.35 m/s for the diagnosis of significant fibrosis, 1.61 m/s for the diagnosis 
of severe fibrosis and 1.87 m/s for the diagnosis of liver cirrhosis (18). 
 
 FACTORS INFLUENCING ARFI ELASTOGRAPHY MEASUREMENTS: 
The most important factor affecting the ARFI elastography score is the liver stiffness which 
is a surrogate marker for the extent of liver fibrosis. However, they are few factors which 
have been noted which affect the shear wave velocity measurements. 
According to Rifai et al. the presence of liver inflammation causes increased shear wave 
velocity as opposed to those with no significant inflammation. They also found a positive 
correlation between the liver and the spleen size and the ARFI measurement (21). Takahashi 
et al. reported a positive correlation with increased ARFI measurements and elevated serum 
aspartate aminotransferase, alanine aminotransferase levels and liver pathological 
inflammation (22). Pathological liver steatosis has been found to be a significant factor which 
can affect liver ARFI measurements. Yoneda et al. suggested that ARFI measurements in 
liver steatosis are slower than normal individuals. Near normal ARFI values were seen in 
patients with NAFLD and mild liver fibrosis. It was suggested that the presence of steatosis 
made the liver softer and thus causing low ARFI measurements (23). Patients with BMI 
greater than 40 kg/ m2 require XL ultrasound probe for ARFI measurements. However the 
standard cut-off values in this subset of patients has not yet been standardised. 
 
LIMITATIONS AND CONTRAINDICATIONS OF ARFI ELASTOGRAPHY: 
There are no significant contraindications or limitation to ARFI elastography evaluation of 
the liver. According to Japanese Society of Ultrasonics in Medicine, ARFI should be avoided 
after administration of few contrast enhanced ultrasound agents as it carries an increased risk 
of cavitation. The limitations of obesity, narrow intercostal space and ascites which were 
encountered by transient elastography, which do not apply for ARFI elastography. Palmeri et 
al, found that ARFI success rate of only 58% in patients with BMI> 40 kg/ m2 (13).  
 
ARFI ELASTOGRAPHY OF LIVER IN CORRELATION WITH TRANSIENT 
ELASTOGRAPHY (TE FibroScan-FS): 
Kirches et al, performed TE measurements of liver in six hundred and sixty six patients and 
compared them to ARFI and sixty eight patients and compared them with the fibrosis stage 
on liver biopsy. The overall success rate for TE was 77.8% ± 28.5% as compared to ARFI 
with a success rate of 93.3% ± 9.87% (P < 0.001). The success rate of liver stiffness 
measurement of 100% was observed in 262 (43.2%) patients by TE compared to 373 patients 
(61.6%, P < 0.001) by ARFI. Significant correlation was found between TE and ARFI (p< 
0.001). Mean ARFI shear wave velocity measurements significantly increased with the stage 
of fibrosis. For patients with no significant fibrosis, the median ARFI value was 1.09 ± 0.13 
m/s and (FS-LS < 7.6 kPa), for patients with significant fibrosis the median ARFI value was 
1.44 ± 0.26 m/s (7.6 < FS-LS ≤ 13.0 kPa); and 2.55± 0.77 m/s for patients with liver cirrhosis 
(13.0 < FS-LS). Cut-off values for patients with no significant fibrosis and patients with liver 
cirrhosis were taken in order to have maximum sensitivity and specificity. A cut-off value for 
ARFI shear wave velocity of 1.29 m/s was had sensitivity of 91.4% and specificity of 92.6% 
for patients with FS-LS < 7.6 kPa and a cut off value of 1.60 m/s for patients with FS-LS > 
13.0 kPa with a sensitivity of 92.3% and specificity of 96.5%. Both the methods have high 
diagnostic accuracy for no significant fibrosis or liver cirrhosis (10).  
 
ADVANTAGES OF ARFI ELASTOGRAPHY OVER TRANSIENT 
ELASTOGRAPHY: 
ARFI as compared with TE has the advantage that it is integrated into a conventional 
ultrasound system. This enables measuring elastography scores of the liver and at the same 
time allows screening of focal liver lesion in patients with suspected chronic liver disease 
with the same ultrasound machine and the probe.  In addition, the site of measurement ARFI 
can be visualised with B-mode ultrasound which allows more exact measurement of liver 
tissue elasticity by excluding small non-parenchymatous areas like the gall bladder, portal 
and biliary radicals within the ROI measurement site.  
 
ARFI can be performed in both the lobes of the liver, which may enable a better overall 
estimation and distribution of liver fibrosis. Multiple biopsies would be required from 
different segments of the liver to assess accurate comparison with ARFI imaging.  An 
advantage of TE over ARFI elastography is the larger measurement area of 4 cm in length, as 
compared to ROI of 1 cm in ARFI.  This shortcoming is overcome by as ARFI elastography 
includes multiple measurements from the liver (18). The success rate of ARFI is better than 
transient elastography. Transient elastography is limited in patients with ascites and body 
mass index > 28 kg/ m2 (10).  
ARFI ELASTOGRAPHY IN NONCIRRHOTIC PORTAL FIBROSIS (NCPF) OR 
IDIOPATHIC PORTAL HYPERTENSION (IPH): 
Noncirrhotic portal fibrosis (NCPF) / Idiopathic portal hypertension (IPH) is a condition 
where in there is sclerosis of the peripheral portal veins, thin fibrous septa with absence of 
cirrhosis, resulting in portal hypertension. On imaging, this entity mimics cirrhosis and is 
difficult to distinguish it from cirrhosis which has a different clinical course and poorer 
prognosis. It is assumed that the stiffer the tissues , greater is the shear wave propagation 
velocity, hence in patients with NCPF/ IPH due to absence of bridging fibrosis, the ARFI 
shear wave velocities are likely to be lesser than liver cirrhosis. Clinically it manifests as 
anaemia, splenomegaly, esophagogastric varices, portal hypertensive gastropathy, ascites, 
and hepatic encephalopathy. Unlike other chronic hepatopathies, it usually does not lead to 
liver cirrhosis and does not develop into hepatocellular carcinoma. The main morbidity in 
these patients is variceal bleeding, which can be easily controlled unlike liver cirrhotic 
patients.  
Liver biopsy is the essential to differentiate NCPF from liver cirrhosis. In order to avoid 
misdiagnosing these patients there is a need for a non invasive test. Seijo et al. reported that 
the liver stiffness measured by transient elastography in NCPH/ IPH is lower than liver 
cirrhosis. However the difference in the liver stiffness between NCPF/ IPH as compared to 
chronic hepatitis was not clear (24).  
Spleen undergoes architectural changes like pulp hyperplasia, congestion due to increased 
blood flow and fibrosis in portal hypertension. Tawalkar et al. suggested that splenic stiffness 
increases with hepatic fibrosis and is independent of age, sex and body mass index. Splenic 
tissue enlargement due to passive spleen congestion and fibrogenesis is likely to cause 
increased splenic stiffness.  
Yoshihiro Furuichi et al. studied 82 subjects in four groups of patients, namely 17 patients of 
NCPF/ IPH, 20 liver cirrhosis (LC) patients, 20 chronic hepatitis (CH) patients which were 
biopsy proven and 20 normal controls (NC). They have studied the median ARFI 
measurements of liver and splenic stiffness, splenic / liver stiffness ratio in these four groups. 
The spleen size was measured as the cross sectional splenic area which is given by the 
formula: Cross sectional area of spleen (cm2) = longest diameter (in cm) x shortest diameter 
(in cm). Splenomegaly was considered if the cross sectional area was greater than 40 cm2. 
They studied the correlation between the spleen size and splenic stiffness. 
They found that the median ARFI elastography values (m/sec) of the liver in NCPF/ IPH 
group was 1.56 (0.98-2.37), LC 2.44 (1.08–3.83), CH 1.81 (1.03–2.36), NC group 1.13 
(0.86–1.53). It was found that the median liver stiffness of the IPH group was lower than the 
liver cirrhosis group (p=0.00077), and was similar to the chronic hepatitis group (p=0.79) and 
was higher than the normal controls (p=0.0022) (25). The median splenic stiffness in (m/sec) 
of IPH was 3.88 (2.69–4.79), LC was 3.18 (2.06–4.52), CH was 2.27 (1.89–2.77), and NC 
was 1.99 (1.10–2.55). The splenic stiffness values of IPH group was higher than LC group 
(p=0.003) and CH group (p=0.00001). The spleen/ liver stiffness ratio was studied. The 
median values (m/ sec) of IPH was 2.47 (1.71–3.34), LC group was1.3 (0.78–2.64), CH was 
1.32 (0.86–2.15), and NC was 1.78 (0.72–2.30). They suggested that the splenic stiffness is 
higher in IPH patients as compared the liver cirrhosis patients (25). The spleen/ liver stiffness 
cut-off value was taken as 1.53 and the AUROC was 0.920, with sensitivity of 1.000, 
specificity of 0.720, PPV of 0.708 and NPV of 1.00 indicating that spleen/ liver stiffness ratio 
is useful to differentiate IPH from liver cirrhosis. 
The cut-off value for spleen stiffness was taken as 2.69 m/s to differentiate between IPH and 
liver cirrhosis. AUROC was 0.997, sensitivity 1.000 (0.895–1.000), specificity 0.950 (0.850–
0.950), PPV0.944 (0.833–0.944), NPV 1.000 (0.895–1.000), and accuracy 0.973 (0.865–
0.973). The above findings in their study concluded that the splenic stiffness and the spleen/ 
liver stiffness ratio are important to specifically diagnose IPH/ NCPF and to differentiate 
from liver cirrhosis and chronic hepatitis (25). 
 In the study done by Yoshihiro Furuichi et al. the spleen size was the largest in the NCPF/ 
IPH group (102.5 cm2), followed by liver cirrhosis group (44cm2), chronic hepatitis group 
(28.9 cm2) and the normal subjects (22.4 cm2).  There was no correlation between spleen size 
and spleen stiffness in each of the groups (rs = -0.081, 0.091, 0.300, 0.071, respectively, p = 
0.742, 0.656, 0.190, 0.757). Hence the spleen size was not the cause of the increase in spleen 
stiffness in IPH. In this study, the liver functions, esophageal varices and radiological 
findings were similar in the IPH patients and the liver cirrhosis group. The size of the spleen 
was larger and stiffer in IPH as compared with liver cirrhosis group. The liver stiffness was 
marked in the liver cirrhosis group as compared with the IPH group. They have suggested 
that it is possible to non-invasively diagnose IPH by splenic stiffness and spleen/ liver 
stiffness ratio by ARFI elastography (25). 
DIAGNOSTIC ACCURACY OF ARFI ELASTOGRAPHY OF LIVER AND SPLEEN 
TO PREDICT PORTAL HYPERTENSION: 
There are published studies which have assessed the diagnostic accuracy of ARFI 
elastography in predicting portal hypertension which show varying results.  
In the first study done by Sirli et al. 157 cirrhotic patients were studied using ARFI and also 
had a recent gastroscopy.  The mean ARFI measurement of liver with significant esophageal 
varices (greater than grade 2) was not significantly different from the patients with no or 
small esophageal varices: 2.73±0.71 vs. 2.8±0.71m/s (p=0.49). There was significant 
difference in the mean ARFI values in patients with variceal bleeding and the without history 
of variceal bleeding: 2.78±0.81 vs.2.77±0.7m/s (p=0.99) (26). 
 
The first study which has assessed the correlation of ARFI elastography with HVPG 
measurements was by Salzl et al. They have evaluated 36 patients with cirrhosis and 12 non 
cirrhotic patients and have obtained good correlation between the liver stiffness 
measurements by ARFI and HVPG (r=0.709). The AUROC for predicting clinically 
significant portal hypertension was 0.874 (26). 
 
Riafai et al. evaluated both the liver and the splenic stiffness in 125 subjects (30 cirrhotics 
with portal hypertension, 70 chronic hepatopathies without portal hypertension and 25 
healthy controls). They have found that the liver stiffness is a better predictor of portal 
hypertension than splenic stiffness (AUROC 0.90 vs 0.68). The liver stiffness cut-off for 
predicting portal hypertension in this study was 1.67m/sec which was lower than the other 
(54). The splenic stiffness cut-off for predicting portal hypertension was 3.29 m/ sec with 
47% sensitivity and 73% specificity.   
 
Gao et al. studied the correlation of liver stiffness and splenic stiffness by ARFI and HVPG 
measurements among 10 patients before and after transjugular intrahepatic porto-systemic 
shunt (TPIS) placement. There mean splenic stiffness values before shunt placement were 
higher than post stenting (3.65±0.32 m/s vs. 3.27±0.30 m/s, p<0.001) (27). There was no 
significant difference in the liver stiffness pre and post TIPS.  
 
Mori et al. published the first study analysing the diagnostic accuracy of liver stiffness and 
the spleen stiffness by ARFI elastography as indicators of portal hypertension to predict 
ascites or esophageal varices in chronic hepatitis C patients.  They found that the spleen 
stiffness and not the liver stiffness was associated with the presence of ascites (p<0.05). The 
AUROC for splenic stiffness to predict ascites was 0.80.There was no association between 
the splenic stiffness and the presence of esophageal varices.  
 
In advanced cirrhosis, they are extra-hepatic factors like hyperdynamic circulation; 
splanchnic vasodilatation and resistance to the portal flow by porto- systemic collaterals 
causes the raise in portal pressure. Thus, the liver stiffness may not represent complex 
changes in impending portal hypertension. The portal hypertension leads to pulp hyperplasia 
resulting in elevated splenic stiffness (28).  
 
Another study was published by Xiao-ping et al. who studied 264 subjects, out of which 60 
were healthy volunteers, 66 with chronic hepatitis who had undergone liver biopsy and 138 
with hepatitis B related cirrhosis. They found significant linear correlations between liver 
(Spearman ρ= 0.87; p < .001) and spleen (Spearman ρ= 0.76; p< .001) stiffness and the 
fibrosis stage. Liver and spleen stiffness values increased as the fibrosis stage increased; 
however there was overlap in liver stiffness were detected in stages 0 and 1 and 1 and 2, and 
splenic stiffness between stages 0 and 1, 1 and 2, and 2 and 3. Liver stiffness cut off values 
were 1.69 m/s for predicting stage 3 or greater (AUROC = 0.99) and 1.88 m/s for stage 4 
(AUROC = 0.97). The spleen stiffness cut off value was 2.72 m/s for stage 4 (AUROC = 
0.96). The liver stiffness was not correlated with the grade of esophageal varices, whereas a 
significant linear correlation (Spearman ρ = 0.65; P < .001) was found between spleen 
stiffness and the grade of esophageal varices. Spleen stiffness cut off value for predicting 
varices was 3.16 m/s (AUROC = 0.83).They suggested that splenic stiffness by ARFI 
elastography can be used to determine the presence and severity of esophageal varices (29). 
 
DIAGNOSTIC ACCURACY OF ARFI ELASTOGRAPHY OF SPLEEN TO 
PREDICT CIRRHOSIS: 
Gallotti et al. were the first to study the splenic stiffness (SS) in 35 healthy volunteers. The 
mean SS value in healthy volunteers was 2.44 m/ sec. Bota et al. studied 82 subjects to 
determine the splenic stiffness (SS) in healthy volunteers and to assess the predictive of SS 
for liver cirrhosis and presence and severity of esophageal varices.  The mean ARFI SS 
values (m/s) in healthy subjects was 2.04±0.28 and 3.10±0.55 in cirrhotic patients 
(p<0.001).They found that the best ARFI SS cut-off value for predicting cirrhosis was 2.51 
m/s (AUROC 0.91, p<0.0001, with 85.2% Se,91.7% Sp, 95.8% PPV, 73.3% NPV and 87.1% 
accuracy). The accuracy increased when liver stiffness (LS) and SS were combined. There 
was no significant difference in SS between patients with esophageal varices (EV) and 
without EV and among those with and without a history of variceal bleed (30).  
DIAGNOSTIC ACCURACY OF ARFI ELASTOGRAPHY OF SPLEEN TO 
PREDICT ESOPHAGEAL VARCIES: 
Takuma Y et al. studied ARFI elastography of the spleen in 340 patients to predict 
esophageal varices among cirrhotic patients. They found that the patients with cirrhosis had 
higher LS and SS values as compared to controls (p< o.0001). The SS values were higher 
among patients with esophageal varices than controls. Higher SS values were noted in 
patients with high risk esophageal varices (EV). SS was found to have highest diagnostic 
accuracy than other non-invasive parameters and was independent of the etiology of 
cirrhosis. SS was also found to have a high NPV and sensitivity regardless of the severity and 
etiology of cirrhosis. The SS cut off value for indentifying patients with esophageal varices 
was 3.18 m/ sec with 98.4% negative predictive value, 98.5% sensitivity, 75.0% accuracy, 
and 0.025 negative likelihood ratio. The SS cut off value  to identify cirrhotic patients with 
high risk esophageal varices was 3.30m/s with a 99.4% negative predictive value, 98.9% 
sensitivity, 72.1% accuracy, and 0.018 negative likelihood ratio (31). The study proposed that 
SS values less than 3.3 m/s ruled out the presence of high-risk varices in patients with 
compensated or decompensated cirrhosis. The AUROC of liver stiffness (LS) to predict EV 
was 0.746 and is therefore useful but not excellent. With increase in portal hypertension, 
there is increase in intrahepatic vascular resistance from accumulation of fibrosis in the 
extracellular matrix. However in this study further increase in LS did not reflect late 
complications of portal hypertension (31). 
Vizzutti et al. showed association between LS and hepatic venous pressure gradient (HVPG). 
The LS correlated well with HVPG when HVPG is less than 10 mm of Hg than when it is 
greater than 10 mm of Hg. Splenomegaly in portal hypertension is due to portal congestion 
and tissue hyperplasia. Some studies showed no difference in portal pressures in patients with 
cirrhosis with or without splenomegaly. Few studies showed that in chronic liver disease, 
there is increase in portal pressure with increase in the spleen size and presence of esophageal 
varices. In this study, 48 patients with normal spleen size had high SS values and 48% had 
EV.  Among these patients there was significant difference in the LS and the platelet count 
between patients with and without EV. They found that platelet count, LS, SS and spleen 
diameter are independent parameters associated with presence of esophageal varices. SS had 
significantly better AUROC than spleen diameter to predict esophageal varices. It is proposed 
that there is increase in diffuse fibrosis of the spleen trabeculae rather than congestion of red 
pulp and tissue hyperplasia that causes increase in SS with normal spleen size.  The limitation 
of this study was that there was no correlation with SS by ARFI elastography and HVPG. 
The failure rate to perform ARFI was 0.8% for LS and 4.5% for SS. They suggested that 
splenic stiffness by ARFI elastography can rule out the presence of esophageal varices, 
indentify the patients with high risk esophageal varices. It can be used as an initial non 
invasive screening tool which is more cost effective than screening endoscopy (31). 
SYSTEMATIC REVIEW AND META-ANALYSIS OF THE DIAGNOSTIC 
ACCURACY OF ARFI ELASTOGRAPHY OF SPLEEN TO PPREDICT 
ESOPHGEAL VARICES IN CHRONIC LIVER DISEASE: 
In a recent publication by Singh et al. a systematic review and meta-analysis of 12 studies 
was done that compared the diagnostic accuracy of splenic stiffness (SS) by ARFI 
elastography with that of endoscopy (EGD) in detecting esophageal varices (EV) in patients 
with chronic liver disease. 
The study showed that SS detected with the presence of EV with 78% sensitivity (95% 
confidence interval [CI], 75%–81%), 76% specificity (95% CI, 72%–79%), a positive 
likelihood ratio (LR) of 3.4 (95% CI, 2.3–4.9), a negative LR of 0.2 (95% CI, 0.1–0.4), and a 
diagnostic odds ratio of 19.3 (95% CI, 7.5–49.8).  
 
In a meta-analysis of 9 studies, SS detected the presence of clinically significant EV with 
81% sensitivity (95% CI, 76%–86%), 66% specificity (95% CI, 61%–69%), a positive LR of 
2.5 (95% CI, 1.7–3.9), a negative LR of 0.2 (95% CI, 0.1–0.5), and a diagnostic odds ratio of 
12.6 (95% CI, 5.5–28.7).  
 
Due to the different elastography techniques and study locations there was significant 
heterogeneity among the studies. They proposed that the current techniques of measuring 
splenic stiffness are limited to detect esophageal varices (32). 
 
 
 
 
NON INVASIVE METHODS TO ASSESS LIVER FIBROSIS: SERUM FIBROSIS 
MARKERS WITH SERUM FIBROSIS SCORES: 
SERUM FIBROSIS MARKERS:  
The serum fibrosis markers have advantage over liver biopsy as they are less expensive, less 
dependence on professional expertise and can be frequently repeated. They can reflect the 
degree of liver fibrosis and can predict clinically relevant outcomes.  They are divided into 
indirect and direct markers of fibrosis. 
INDIRECT MARKERS OF LIVER FIBROSIS (Class II- simple lab tests):  
The diagnostic performance of these tests as „surrogate markers‟ of liver fibrosis have been 
studied extensively. These include AST, ALT which are markers of cytolysis, gamma GT, 
bilirubin which indicates cholestasis, INR, cholesterol, Apo A1, haptoglobulin and N-glycans 
which indicate hepatocyte function and platelet count which indicate hypersplenism due to 
portal hypertension. These are also surrogate markers for liver inflammation and steatosis and 
can predict progression of fibrosis (33). They are about 20 indices or scores which are 
multiparameteric reported in literature based on routine lab tests. The serum tests which are 
biomarkers for liver fibrosis are Aspartate aminotransferase (AST)-to-platelet ratio index 
(APRI), FIB-4, Forns index, Fibroindex, Fibrotest, Fibrometer and Hepascore. The advantage 
of APRI, the Forns index and FIB-4 are that they are based on routine blood tests and thus are 
less expensive and more frequently used than others.  Of these tests, APRI and Fibrotest have 
been proposed for clinical application. AST- to platelet ratio (APRI) test has been found to be 
a reliable marker to non- invasively predict significant fibrosis and cirrhosis in patients with 
chronic hepatitis C AUC of 0.80 (34).  The FibroTest which is a combination of bilirubin, 
alpha 2 macroglobulin, gamma GT, Apo A1 and haptoglobulin is the most validated test for 
estimating liver fibrosis.  
In a meta- analysis of 14 studies of various indirect serum fibrosis markers including APRI 
and FibroTest showed that they cannot reliably differentiae different grade of fibrosis as they 
can be influenced by multiple factors including ongoing drug therapies (35).   
For portal hypertension Child- Pugh score correlates with HVPG and the prevalence of 
varices in the cirrhotic patients. Platelet count has been found to be independently correlates 
with the grade of esophageal varices in many studies.  
DIRECT MARKERS OF LIVER FIBROSIS (Class 1):  
The direct markers are biochemical markers assessed in peripheral blood which assess the 
changes in the content and composition of the extracellular matrix proteins, matrix modifying 
enzymes and their inhibitors in the liver. They are expensive tests and have been proposed to 
be used in various algorithms. They provide good discrimination between patients with and 
without liver fibrosis and have promising approach in future (33). 
SERUM FIBROSIS SCORES: 
Serum fibrosis scores that are based only on indirect fibrosis markers show poor 
discrimination between different stages of fibrosis than the scores based on both direct and 
indirect fibrosis markers. Most of these fibrosis scores have been primarily validated in HCV, 
HIV/ HCV coinfected patients and HBV infections. The advantage of APRI, the Forns index 
and FIB-4 are that they are based on routine blood tests and thus are less expensive and more 
frequently used than others (36). Lin ZH et al. in a meta-analysis of 40 studies assessed the 
performance of APRI as non invasive tool as an alternate to liver biopsy in HCV 
monoinfected and HIV and HCV coinfected patients. The summary AUROC of the APRI for 
the diagnosis of significant fibrosis, severe fibrosis, and cirrhosis were 0.77, 0.80, and 0.83, 
respectively. For significant fibrosis, an APRI threshold of 0.7 was 77% sensitive and 72% 
specific. For severe fibrosis, a threshold of 1.0 was 61% sensitive and 64% specific. For 
cirrhosis, a threshold of 1.0 was 76% sensitive and 72% specific. Hence, it was found that 
APRI can identify hepatitis C-related fibrosis with a moderate degree of accuracy (37).  Jin et 
al. assessed in a meta-analysis of 9 studies which included 1798 patients, the efficacy of 
APRI as alternative for liver biopsy for predicting significant fibrosis and cirrhosis in patients 
with hepatitis B. AUROC of the APRI for significant fibrosis and cirrhosis were 0.79 and 
0.75, respectively. APRI cut off for significant fibrosis was 0.5 was 84% sensitive and 41% 
specific. At the cut off of 1.5, the summary sensitivity and specificity were 49% and 84%, 
respectively. APRI threshold for cirrhosis was 1.0-1.5 was 54% sensitive and 78% specific. 
At the cut off of 2.0, the summary sensitivity and specificity were 28% and 87%, 
respectively. Hence in patients with hepatitis B related liver disease, APRI showed limited 
value in to assess significant fibrosis and cirrhosis (38). 
 
OTHER IMAGING MODLAITIES TO ASSESS PORTAL HYPERTENSION: 
• Ultrasound 
• Doppler  
• CT  
• MRI with MR elastography (MRE) 
 
 GRAY SCALE ULTRASOUND IMAGING IN CHRONIC LIVER DISEASE: 
Ultrasound is the most commonly available, non invasive imaging modality used for 
diagnosis and surveillance of patients with chronic liver disease. For the diagnosis of 
cirrhosis on conventional ultrasound there are changes in liver morphology and signs of 
portal hypertension. The liver morphological changes include nodular surface, coarse 
echotexture, left lobe to right lobe ratio greater than 1.3, caudate lobe hypertrophy indicated 
by ratio of caudate lobe to right lobe ratio greater than 0.65 and reduction in the medial 
segment of the left lobe of the liver. Of these signs, liver surface nodularity has been founder 
to have higher accuracy. Combination of liver surface nodularity and portal vein velocity 
more than 12 cm per second is 80 % accurate to differentiate between significant fibrosis and 
cirrhosis in patients with chronic hepatitis (39). There are studies in the literature which have 
looked at the diagnostic accuracy of gray scale ultrasound for early fibrosis, significant 
fibrosis, severe fibrosis and cirrhosis of liver. Few scoring systems have also been proposed. 
Choong et al used three liver morphologic parameters on ultrasound to grade liver in patients 
with CLD. They are liver echotexture, liver surface and liver edge. These three parameters 
were compared with the liver histopathological score of fibrosis. They have found that 
ultrasound has low sensitivity to identify or rule out early fibrosis. Surface nodularity on 
ultrasound best predicts significant liver fibrosis on histopathology. Combined evaluation of 
liver surface, texture and edge has highest sensitivity (63%) than each of the individual 
parameters to identify significant fibrosis on ultrasound. Liver edge has least sensitivity but 
has high specificity which would help to rule out significant fibrosis and cirrhosis (40).  
Afzal et al. used six morphological parameters on gray scale ultrasound to obtain an 
ultrasound score to differentiate between mild/ no fibrosis and significant fibrosis. They have 
used liver echotexture, liver edge, liver surface, liver size, portal vein size and splenic size. 
Liver parenchymal echotexture if homogenous was scored as 0, coarse as 1 and highly 
inhomogeneous as 2. Smooth liver surface was scored as 0, irregular surface as 1 and nodular 
surface as 2. A sharp liver edge was scored as 0, blunted as 1 and rounded edge as 2. Normal 
liver size was scored as 0, enlarged liver (> 15 cm measured in the mid clavicular line) as 1 
and shrunken liver (< 10 cm measured in the mid clavicular line) as 2.  Portal vein diameter 
less than 13 cm was scored as 0 and greater than 13 cm was scored as 1 and spleen size less 
than 13 cm was scored as 0 and greater than 13 cm was scored as 1.They have noted that the 
liver surface evaluation had highest specificity (86%) and reproducibility for staging liver 
fibrosis. Liver edge was also found to have good sensitivity (84%) for liver fibrosis which 
was not found in the other studies. The presence of steatosis affects the assessment of liver 
echotexture which can be seen in patients with chronic viral hepatitis (41).  
SECOND LINE IMAGING METHODS FOR LIVER CIRRHOSIS AND PORTAL 
HYPERTENSION: 
Computed tomography (CT) and magnetic resonance imaging (MRI) provide accurate 
visualization of the liver parenchyma and the portal system. CT is a reliable indicator for 
large esophageal varices with a specificity of 90- 100% and sensitivity of 84- 100%, however 
is a poor indicator of small varices.  Blood flow in the portal vein and the azygos vein can be 
studied using dynamic contrast enhanced CT and MRI and phase contrast MR angiography.  
Blood flow in the azygos vein which is measured by MRI correlates with the presence of 
esophageal varices and increased risk of variceal bleeding. Estimation of portal fraction of 
liver perfusion and mean transit time at MRI has been shown to correlate with HVPG (42). 
MR ELASTOGRAPHY (MRE):  
MRE is a novel technique to assess liver fibrosis.  The measurements in MRE are obtained 
using motion sensitive MR sequences with application of acoustic waves.  Preliminary tests 
have shown that is can predict the stage of liver fibrosis in chronic liver disease.  Splenic 
stiffness measured by MRE has been found to correlate well with the liver stiffness and might 
better predict portal pressure. MRE as compared with FibroScan does not require acoustic 
window, freely- oriented field of view and does not depend on patient body habitus. It is 
expensive and time consuming and is used for patients who are undergoing MRI for other 
reasons (42). 
 
INVASIVE METHODS TO ASSESS PORTAL HYPERTENSION: 
      (i). Hepatic venous pressure gradient (HVPG). 
(ii). Endoscopy for esophageal varices. 
(iii). Liver biopsy. 
 
HEPATIC VENOUS PRESSURE GRADIENT (HVPG): 
HVPG is considered the gold standard for measurement of portal pressure. It is a safe and a 
reproducible technique used to measure portal pressure gradient (PPG) in cirrhosis 
(sinusoidal portal hypertension). The portal pressure gradient (PPG) is the pressure difference 
between the portal vein and the IVC and it represents the portal perfusion pressure. The portal 
pressure is measured via the transhepatic or transvenous catheterization of the portal vein and 
the IVC pressure is measured to obtain the portal pressure gradient (PPG).   
 
Hepatic venous pressure gradient (HVPG) is defined as the difference between wedge hepatic 
venous pressure (WHVP) and free hepatic venous pressure (FHVP). Wedge hepatic pressure 
is based on the concept that is the hepatic vein outflow is blocked by a „wedged‟ catheter, the 
static column of blood transmits the pressure from the hepatic sinusoids. Hence WHVP 
represents the hepatic sinusoidal pressure and not the portal pressure. As the intersinusoidal 
communications are lost in cirrhosis due to fibrosis, septa and regenerative nodule formation, 
the measurement of sinusoidal pressure will reflect the portal pressure. WHVP has been 
found to adequately reflect portal pressures in alcoholic liver disease, hepatitis C and B 
related chronic liver disease (43). The use of balloon tipped catheters has been recommended 
over wedged catheter as it senses a larger volume of liver circulation, thereby increasing the 
reliability and accuracy of measurement. 
 
USE OF HVPG IN THE CLASSIFICATION OF PORTAL HYPERTENSION: 
HVPG is a strong independent prognostic indicator in patients with compensated and 
decompensated cirrhosis. Among patients with an unknown cause for portal hypertension, 
elevated WHVP and HVPG are due to increase in sinusoidal pressure, of which the most 
common cause is cirrhosis. Normal HVPG and WHVP indicate presinisoidal portal 
hypertension, and in post sinusoidal portal hypertension both the FHVP and WHVP are 
increased. 
HVPG IN COMPENSATED CIRRHOSIS: 
Subclinical portal hypertension is when the HVPG is 6-9 mm of Hg with a negligible risk of 
developing complications related to portal hypertension. Clinically significant portal 
hypertension (CSPH) is seen when the HVPG is greater than 10 mm of Hg. At these portal 
pressures the patients with compensated cirrhosis are at an increased risk for decompensation 
and can develop complications like ascites, varices and hepatorenal syndrome and 
hepatocellular carcinoma (44). Increase risk of variceal bleeding can occur when the HVPG 
exceeds 12 mm of Hg. The mortality of patients increases if the HVPG is greater than 16 mm 
of Hg (45). HVPG when measured within 48 hours of admission following an acute variceal 
bleeding predicts the failure of haemostasis and poor 1 year survival (16). 
HVPG IN DECOMPENSATED CIRRHOSIS: 
HVPG greater than 16 mm of Hg is associated with increased risk of variceal bleeding and 
mortality. There is increased mortality in patients with alcoholic cirrhosis with acute 
alcoholic hepatitis if the HVPG is greater than 22 mm Hg(46). The risk of spontaneous 
bacterial peritonitis increases when the HVPG is greater than 30 mm of Hg (47). In patients 
with decompensated cirrhosis for liver transplantation, HVPG is an independent prognostic 
indicator from Model for End- Stage Liver Disease score (MELD) (48). HVPG greater than 
10 mm of Hg is a contraindication for liver transplantation as these patients have high 
incidence of hepatic decompensation within 3 months (16, 17). 
HVPG FOR ASSESSMENT OF THE HEMODYNAMIC RESPONSE TO 
PHARMACOLOGICAL THERAPY FOR PORTAL HYPERTENSION: 
Good hemodynamic response is when the HVPG has reduced to 12 mm Hg or 20 % of 
baseline measurements due to pharmacological therapy or improvement in liver disease. By 
achieving the target portal pressure, there is a reduction in the risk of complications related to 
portal hypertension.  Failure to attain the target portal pressure is an independent risk factor 
for variceal bleed (50). 
HVPG IN EVALUATION OF PROGRESSION AND REGRESSION OF CHRONIC 
LIVER DISEASE: 
Studies have shown that HVPG increases with increase in histological grade of liver fibrosis 
and decreases in response to antiviral therapy in patients with chronic viral hepatitis (51).  
Hence serial measurements can be used to monitoring progression and regression in response 
to antiviral therapy in patients with hepatitis C related chronic liver disease (19).  
HVPG IN POST LIVER TRANSPLANTATION: 
Among patients undergoing liver transplantation, HVPG is an excellent tool for assessment 
of highest risk patients for HCV recurrence and post transplant hepatic decompensation. 
HVPG > 6 mm of Hg shows highest risk of post transplant HCV recurrence and cirrhosis 
which was found to be more reliable than liver biopsy (1). HVPG also demonstrates the 
changes to antiviral therapy in HCV recurrence post liver transplant and is correlates well 
with liver histology (52). 
 
 
 
RELATIVE CONTRAINDICATION OF HVPG: 
The relative contraindications for HVPG are platelet count less than 20, 000 or prothrombin 
time less than 30%. The procedure can be performed with fresh frozen plasma replacement. 
Allergy to iodinated contrast medium is also a relative contraindication as HVPG can be 
performed using carbon dioxide. Previous episode of cardiac arrhythmias when the catheter 
was removed from right atrium is a relative contraindication (2).  
LIMITATIONS OF HVPG: 
In conditions where the increased resistance is predominantly presinisoidal, HVPG does not 
accurately represent portal pressure gradient.  
Communications between the hepatic veins may interfere with wedge hepatic pressure 
gradient measurements (2).  
 
ENDOSCOPY:  
Upper GI endoscopy is considered as gold standard for evaluation and endoscopic 
management of varices (53).  Endoscopy identifies esophageal, gastric and rarely ectopic 
duodenal varices. The risk of bleeding from esophageal varices (EV) is proportional to the 
size of the varices and presence of „high risk signs‟. Size of esophageal varices is graded into 
small, medium and large. Small esophageal varices are veins which are minimally elevated 
but they do not disappear on insufflation. Medium varices are tortuous veins which occupy 
less than one third of the esophageal lumen. Large varices are tortuous veins occupying 
greater than one third if esophageal lumen (54). Esophageal varices is simplified and 
classified as small and large based on size less than or greater than 5 mm (53).  
The presence of red wales and red spots indicate high risk of variceal bleed and require 
prompt primary prophylaxis even in the presence of small varices (54). Patients with 
advanced cirrhosis (Child-Pugh B and C) are also at increased risk of variceal bleed.  
 Gastroesophageal varices (GOV) account for 5-10% of GI bleed. They are an extension of 
esophageal varices and are of 2 types, GOV1 which are along the lesser curvature of the 
stomach which are more common, and GOV2 along the fundus. Isolated gastric varices 
(IGV) are of two types; IGV1 are located at the fundus and IGV2 are located in the body, 
antrum and the pylorus. Splenic vein thrombosis should be ruled out in type 1 isolated gastric 
varices (2).  GOV1 and isolated gastric varices attain are larger in size and attain greater wall 
tension at lower portal pressure than esophageal varices (HVPG 10-12 mm of Hg). 
Portal hypertensive gastropathy (PHG) is very common in patients with cirrhosis, the 
prevalence ranges from 11 to 80% (2).  
 
Esophageal varices are seen in 30- 40% of patients with compensated cirrhosis and 60% in 
decompensated cirrhosis. Hence endoscopy is mandatory in newly diagnosed patient with 
cirrhosis to screen for esophageal varices. Among the patients without esophageal varices, 5-
10% develops them every year; hence endoscopy should be done every 2-3 years in 
compensated cirrhosis (2). Patients with poor liver function and HVPG greater than 10 mm of 
Hg are at a higher risk of variceal bleed and must undergo endoscopy at shorter intervals.  
Small varices increase at the rate of 10-15 % per year and endoscopy should be repeated 1-2 
yearly (53). 
 
Variceal pressure can be measured endoscopically by direct puncture of the varices or by 
using endoscopic pressure sensitive gauge. The second method is more sensitive to assess 
pharmacological response for portal hypertension. However it requires specific training and 
use predominantly for research purposes (55). 
 
LIVER BIOPSY: 
Liver biopsy is a gold standard for assessing cirrhosis. It is an important tool in assessing and 
grading liver fibrosis and for making therapeutic decisions (56). Liver biopsy has an 
important role in the diagnosis of intrahepatic portal hypertension and has limited role in the 
prehepatic and post hepatic causes of portal hypertension. In patients with portal vein 
thrombosis, liver biopsy is indicated when there is cirrhosis or nodular regenerative 
hyperplasia. In Budd-Chari syndrome, it is indicated when the clinical suspicion is high but 
the imaging fails to demonstrate large hepatic veins or IVC obstruction (57). Liver biopsy can 
assess the severity of portal hypertension in cirrhosis. Higher HVPG values and clinical 
decompensation are associated with small size nodules with increased septal thickness on 
histology (58).  
Newer technology like quantitative computer-assisted digital-image analysis (DIA) of 
histological liver sections has recently been validated for assessing liver fibrosis (as fibrosis 
area). Studies have shown that DIA is better than conventional scoring systems for liver 
fibrosis (eg: Ishak score) and should be used to validate studies assessing non invasive 
markers of liver fibrosis and liver stiffness. According to Calvaruso et al. the fibrosis staging 
using DIA correlated well with the HVPG measurements in patients with post transplant 
HCV infection (59). DIA has also been validated with HVPG measurements in patients with 
cirrhosis (60). The routes of liver biopsy are percutaneous biopsy, Transjugular biopsy 
(TJLB), laparoscopic biopsy, Biopsy or fine needle aspiration under ultrasonography or 
computed tomography and Peroperative biopsy. 
 
 
 
 
TRANSJUGULAR LIVER BIOPSY (TJLB): 
TJLB is indicated in situations where percutaneous liver biopsy is contraindicated due to 
ascites, coagulopathy, acute liver failure and liver transplant recipients. It also allows 
measurement of hepatic venous pressure gradient in the same sitting which has a prognostic 
value for survival and also assesses response to pharmacologic treatment of portal 
hypertension. 
ADEQUATE LIVER BIOPSY SPECIMEN: 
For histological diagnosis of chronic liver disease, liver specimen should be atleast 15 mm 
with greater than 6 complete portal tracts (CPTs). Ideally, the biopsy specimen should be 20-
25 mm in length with greater than 11 CPTs to reliably stage and grade chronic liver disease 
(61).  
LIMITATIONS OF LIVER BIOPSY: 
It is an invasive procedure which requires inpatient care and post procedural monitoring for 
24 hours. Sampling error can occur as liver fibrosis is not uniform throughout the liver. Liver 
biopsy samples only 1/ 50,000 Th part of the liver parenchyma; hence it may underestimate 
the degree and extent of liver fibrosis. Liver biopsy specimen may be inadequate or have 
fragmented specimens. Inter and intra-observer variability in interpretation especially in 
macronodular cirrhosis. Complications rate of 7% including hemorrhage, biliary leak or 
fistula. 
 
 
 
 SCORING SYSTEMS OF LIVER FIBROSIS ON HISTOPATHOLOGY: 
They are several systems which have been proposed to classify the fibrosis into various 
stages based on the amount of collagen staining on liver biopsy specimen. The staging 
systems used are the Histology activity index (HAI: Knodell score), Ishak score modification 
of the HAI sore and the METAVIR score.  
The METAVIR score is a semiquantitiative classification system which scores the 
necroinflamamtion and the degree of liver fibrosis. It recognises subtler variations in the 
degree of liver fibrosis as compared to the Knodell fibrosis score. It is a well validated 
scoring system with good inter and intra-observer reproducibility. Fibrosis is assessed on a 
scale of 0 to 4. Clinically significant fibrosis is defined as fibrosis greater than F2.  
F0- no fibrosis 
F1- portal fibrosis without septae 
F2- portal fibrosis with few septae 
F3- numerous septae without cirrhosis 
F4- cirrhosis (62) 
The necroinflamamtion on liver biopsy specimen is graded as A0-A3. 
A0- no activity 
A1- mild activity 
A2- moderate activity  
A3- severe activity (62) 
 
MATERIALS AND METHODS: 
STUDY DESIGN: Test of diagnostic accuracy.  Prospective study approved by Institutional 
Research Board (IRB). IRB study number: 22X945 
SETTING: Christian Medical College (CMC) Vellore is a tertiary care centre in northern 
Tamil Nadu. The institution was established in 1900 and is now a 2700 bedded hospital. The 
annual outpatient visits is around 1.9 million with inpatient admissions of ~ 120,000. The 
Department of Radiology in CMC, Vellore was established in 1936. Digitalization of the 
system and introduction of PACS (Picture Archival and Communication System) was done in 
the year 2000. The Department functions independently with around 70 radiologists. The 
radiological investigations routinely performed are radiographs, IVU, barium studies, 
ultrasonography and Doppler studies, mammograms, CT and MRI. 
METHODOLOGY: 
SAMPLE SIZE:  
The total sample size calculated was 44. 22 NCPF patients and 22 patients with other causes 
of cirrhosis were required for the study. 
INCLUSION CRITERIA OF THE STUDY POPULATION: 
All the patients who are admitted in CMC for liver biopsy with a clinical diagnosis of 
cryptogenic cirrhosis for percutaneous ultrasound guided liver biopsy, percutaneous blind 
liver biopsy or trans-jugular liver biopsy from September 2012 to October 2013. Patients with 
who had liver biopsy in the past were also studied. 39 patients with a liver biopsy were 
included and ARFI elastography of the liver and the spleen was performed. 9 patients who 
were clinically suspected to have NCPF were also studied. 
58 cases of portal hypertension of any etiology were studied to assess the correlation of ARFI 
elastography of the liver and the spleen with the presence of high risk esophageal varices on 
endoscopy. This group includes 39 liver biopsy cases, 9 suspected NCPF cases without liver 
biopsy and 10 cases of portal hypertension due to other known etiologies. 
EXCLUSION CRITERIA:  
Patients who cannot co-operate for breath hold during the ARFI elastography study, children 
less than 5 years of age and patients with BMI greater than 40 kg/ m2 were excluded from the 
study. 
SAMPLING AND CONSENT: 
The prospective study patients were admitted for liver biopsy under the department of 
Hepatology. All patients who fulfilled the inclusion criteria were included in the study. 
Personal data, clinical, biochemical, ultrasound findings and median ARFI shear wave 
velocity scores of the liver and the spleen were entered into a coded – numbered proforma 
(Appendix 1). Informed consent was obtained from the patient / patient`s relative prior to 
ultrasound in accordance with the ethical guidelines of Helsinki declaration and approved by 
the Institutional review board of the hospital. The consent form and the patient‟s information 
sheet are attached in Appendix 2. 
 
 
 
 
 
VARIABLES: 
The various variables studied were patient‟s age, gender, BMI, clinical presentation, 
haemoglobin, platelet count, serum bilirubin, serum albumin, AST, ALT, PT with INR, 
CHILD PUGH score. On imaging, the B- mode ultrasound parameters studied were liver 
size, liver echotexture, liver surface, liver edge, periportal echogenicity, portal vein size, size 
of spleen, spleen area (product of maximum spleen length and spleen width at the hilum), 
presence of collaterals and ascites. ARFI elastography parameters measured were liver 
stiffness (LS), spleen stiffness (SS) and ratio of spleen stiffness and liver stiffness (LS/ SS).  
ULTRASOUND SCANNER: 
Acoustic radiation force impulse (ARFI) elastography is a radiation force based imaging 
method combined with conventional B mode ultrasound (Acuson S 2000, SEIMENS Medical 
Solutions). The „Virtual Touch Tissue Quantification‟ (VTQ) provided by SEIMENS 
quantifies the tissue stiffness by shear wave velocity of acoustic radiation force impulse 
displacement within the human tissues. It is represented as m/sec and is proportional to the 
square root of the tissue elasticity.  
To obtain a baseline signal, an initial ultrasonic pulse at diagnostic intensity level is 
transmitted by the transducer. Subsequently, a short duration (0.3 s) high intensity acoustic 
„pushing pulse‟ is applied by the transducer, followed by a series of diagnostic intensity 
pulses.  The diagnostic pulses are used to track the displacement of the tissues caused by the 
pushing pulse. The response of the tissues to the radiation force is assessed by conventional 
B-mode imaging pulses, and are represented shear wave velocity measurements as m/ sec. 
 
 
PROTOCOL FOR LIVER AND SPLEEN STIFFNESS MEASURMNENT BY ARFI 
ELASTOGRAPHY: 
ARFI elastography Virtual Touch Tissue Quantification imaging is performed with curved 
array 4 MHz, B-mode ultrasound transducer. Conventional ultrasound was performed in all 
patients.  
For liver stiffness (LS) assessment the patient lies in the dorsal decubitus position with the 
right arm maximally abducted. The right lobe of the liver is assessed through the intercostal 
approach.  The patient was asked to hold the breath for 1-2 seconds while measurements were 
taken. The Region of interest (ROI) cursor was placed 2-3 cm below the liver capsule not 
exceeding a depth of 6 cm from the liver capsule. The gall bladder, visible vessels and the 
biliary radicals were avoided within the ROI cursor. Total of 10 measurements were taken 
from segments 5 and 8 of the liver. The median shear wave velocity measurement was taken 
for analysis. The interquartile range between the measurements for accurate assessment was 
taken to be less than 25%. (13). 
For splenic stiffness assessment (SS), the patient lies in the right lateral decubitus position 
with left arm in maximum abduction. The ROI was placed 2-3 cm below the splenic capsule 
and 10 measurements were taken from the mid and the lower pole of the spleen. The median 
splenic shear wave velocity measurement was taken for analysis.  
The ratio of splenic stiffness (SS) to liver stiffness (LS) ratio was taken. The best parameter 
to predict the stage of liver fibrosis, to differentiate NCPF from other causes of cirrhosis and 
best parameter to predict clinically significant portal hypertension using ARFI elastography 
was studied.  
 
ARFI ELASTOGRAPHY SHEAR WAVE VELOCITY (SWV) CUT-OFF VALUES: 
LIVER FIBROSIS  STAGE ARFI SWV LIVER STIFFNESS (LS) 
CUT OFF VALUES : 
Normal (F0) 1. 2 cm / sec 
Mild fibrosis (F1) 1.21-1.34 cm / sec 
Significant fibrosis (F2- F3) 1.35- 1.86 cm / sec 
Cirrhosis > 1.87 cm / sec 
Table1: ARFI elastography liver stiffness (LS) velocity ranges corresponding to grades of 
liver fibrosis (18). 
NCPF ARFI SWV CUT-OFF VALUES 
Liver stiffness (LS) <1.65 cm / sec 
Spleen stiffness (SS) >2.69 cm /sec 
SS/ LS  >1.53 
Table2: ARFI elastography cut off values of LS, SS and SS/LS to indentify NCPF from other 
causes of cirrhosis (25). 
SPLEEN  ARFI SWV SPLEEN STIFFNESS (SS) 
CUT- OFF VALUES : 
Normal  <2.0 cm / sec 
Cirrhosis >2.51 cm /sec 
Presence of esophageal varices on 
endoscopy 
>3.16 cm / sec 
Significant esophageal varices on endoscopy >3.3 cm / sec 
Table 3: ARFI elastography spleen stiffness (SS) velocity ranges (31). 
 
  
Figure1: ARFI elastography of the liver showing the ROI placement for liver stiffness 
assessment (LS). 
 
Figure 2: Sample report of the liver stiffness (LS) measurements taken by ARFI elastography. 
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Figure3: ARFI elastography of the spleen showing the ROI placement for spleen stiffness 
assessment (SS). 
REFERENCE STANDARDS: 
The reference standard for staging liver fibrosis was the liver biopsy. For assessing clinically 
significant portal hypertension, the reference standards were HVPG for patients who 
underwent TJLB and by the presence of high risk esophageal varices on endoscopy. 
LIVER HISTOPATHOLOGY: 
Liver biopsy was taken as the gold standard to grade the liver fibrosis. The patients 
underwent liver biopsy either by percutaneous ultrasound guided liver biopsy, trans-jugular 
liver biopsy or percutaneous blind liver biopsy. The fibrosis on liver biopsy for graded as nil, 
mild, moderate, severe and cirrhosis corresponding to METAVIR staging of F0-F4. > 
Significant liver fibrosis was taken as >F2 stage on histopathology (18). 
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HEPATIC VENOUS PRESSURE GRADIENT (HVPG): 
HVPG was taken as the gold standard for measuring portal pressures. Measurements were 
taken using catheter wedge method for the subgroup of patients who underwent Transjugular 
liver biopsy (TJLB).  Clinically significant portal hypertension (CSPH) was taken as HVPG 
> 10 mm of Hg (44, 45). 
ENDOSCOPY: 
Clinically significant portal hypertension (CSPH) on endoscopy was represented by the 
presence of high risk esophageal varices or severe portal hypertensive gastropathy on 
endoscopy. Liver stiffness cut off of > 1.67 cm/ sec and spleen stiffness cut-off of > 3.3 cm/ 
sec was used (31). 
STATISICAL ANALYSIS: 
Statistical analysis was performed with SPSS version 18.0 software; α = .05 was considered 
the significance level. Quantitative liver stiffness variables were expressed as mean SD. The 
agreement between the grades of liver fibrosis on biopsy and liver stiffness (LS), spleen 
stiffness (SS) and ratio of spleen stiffness to liver stiffness (SS/LS) was assessed using kappa 
statistics. Spearman correlation was done to assess the liver stiffness velocity scores with 
grades of liver fibrosis on biopsy. Mann-Whitney u test is performed to see whether the 
stiffness values changes between significant and non-significant liver fibrosis. Chi-square 
test/ fisher‟s exact test was used to analyze the association between stiffness grades and 
ultrasound parameters.  
 
 
 
                                                    RESULTS: 
STUDY POPULATION:  
48 cases with preliminary diagnosis of cryptogenic cirrhosis were studied. 39 cases had liver 
biopsy. 11 cases (28%) were proven to be NCPF on biopsy. The rest of the 28 cases were 
autoimmune chronic liver disease, cryptogenic cirrhosis, Wilson‟s disease, drug induced 
hepatitis, Non alcoholic fatty liver disease, Thalassemia and HBV related chronic liver 
disease. 9 cases were clinically suspected to have NCPF who did not undergo liver biopsy 
were also studied.  
58 cases of portal hypertension of any etiology were studied to assess the correlation of ARFI 
elastography of the liver and the spleen with the presence of high risk esophageal varices on 
endoscopy. This group includes 39 liver biopsy cases, 9 suspected NCPF cases without liver 
biopsy and 10 cases of portal hypertension due to other known etiologies 
 
Figure 4: Graph showing the frequency and the spectrum of the final diagnosis on liver 
biopsy. 
AGE DISTRIBUTION: Of the 39 cases of liver biopsy, the median age was 35 years, and 
minimum age of 6 and maximum age was 65 years. 
SEX DISTRIBUTION:  
 
Figure 5: Graph showing the sex distribution between the study populations. 
 
Of the 39 patients 23 were male and 16 were female. 
 
GEOGRAPHIC DISTRIBUTION: 
 
Figure 6: Graph showing the spectrum of geographic distribution of the liver biopsy patients.  
 
Of the 39 patients, 9 were from Tamil Nadu, 7 from West Bengal, 6 from Bangladesh, 6 from 
AP,4 from Jharkhand, 3 from Bihar, and one each from Kerala, Maharashtra, Orissa and 
Punjab. 
CLINICAL FEATURES: 
 
 
 
Figure 7: Graph showing the frequency of liver biopsy patients with jaundice at the time of 
the study.  
Only 8 of the 39 patients had jaundice at the time of the study. 
 
Figure 8: Graph showing the frequency of liver biopsy patients with ascites at the time of the 
study. 
11 patients had ascites at the time of the study. 
 
Figure 9: Graph showing the frequency of liver biopsy patients with recent upper 
gastrointestinal (GI) bleed at the time of the study. 
4 patients had recent upper GI bleed before the study. 
 
Figure 10: Graph showing the frequency of liver biopsy patients with the grades of CHILD 
PUGH score at the time of the study. 
 
26 patients (66.7%) were CHILD A, 9 patients were CHILD B and 4 patients (10.3%) were 
CHILD C.  
GRAY SCALE ULTRASOUND EVALUATION OF LIVER AT THE TIME OF ARFI 
ELASTOGRAPHY: 
The gray scale parameters analysed were in the liver were size, echotexture, surface, edge, 
volume redistribution and the presence of periportal echogenicity. 
Of the 39 patients, 24 had shrunken liver, 32 had coarse echotexture, 29 had surface 
irregularity, 20 had blunted liver edge, 16 had volume redistribution and 4 had periportal 
echogenicity. 
 
INDICATORS OF PORTAL HYPERTENSION ON GRAY SCALE ULTRASOUND 
AT THE TIME OF ARFI ELASTOGRAPHY: 
The ultrasound parameters evaluated were the presence of portal vein dilatation (>13 mm), 
splenomegaly (>13 cm) and the presence of porto-systemic collaterals. 14 patients had dilated 
portal vein, 28 had splenomegaly and 7 had porto-systemic collaterals. 
 
LIVER STIFFNESS (LS) SHEAR WAVE VELOCITY MEASUREMENTS BY ARFI 
ELASTOGRAPHY: 
Grades of liver fibrosis NIL  
(F0) 
MILD (F1) MODERATE 
(F2-3) 
CIRRHOSIS  
(F4) 
Number of cases 3 19 3 14 
Median LS velocity 1.18 1.87 2.09 2.61 
Mean LS velocity 1.23 1.96 2.4 2.66 
Standard deviation 0.10 0.75 1.00 0.59 
Minimum velocity 1.17 1.0 1.59 1.54 
Maximum velocity 1.36 3.5 3.52 3.73 
Table 4: The liver stiffness (LS) median, mean velocities, standard deviation, and the velocity 
ranges as compared to the grades of fibrosis on biopsy. Shear wave velocities in cm/ sec. 
 
Figure 11: Graph showing the frequency of liver stiffness (LS) velocity ranges among the 
liver biopsy patients. 
 
 
Of the 39 patients, the liver stiffness (LS) velocity ranges were 3 normal velocities, 19 had 
mild fibrosis range, 3 had moderate fibrosis range and 14 had cirrhotic range. 
SPLEEN STIFFNESS (SS) SHEAR WAVE VELOCITY MEASUREMENTS BY ARFI 
ELASTOGRAPHY: 
 
Figure 12: Graph showing the frequency of spleen stiffness (SS) velocity ranges among liver 
biopsy patients. 
 Grades of liver fibrosis NIL  
(F0) 
MILD 
(F1) 
MODERATE  
(F2-3) 
CIRRHOSIS  
(F4) 
Number of cases 3 17 3 14 
Median LS velocity NA 2.92 3.01 3.05 
Standard deviation NA 0.41 0.57 0.31 
Minimum velocity NA 2.47 2.35 2.59 
Maximum velocity NA 3.82 3.43 3.72 
NA- Spleen stiffness was not assessed.  
Table 5: Median velocities, standard deviation, and the velocity ranges of spleen stiffness 
(SS) as compared to the grades of liver fibrosis on biopsy. 
 
Of the 39 patients, the spleen stiffness (SS) velocity ranges were not assessed out of which 1 
had splenectomy and 2 patients could not co-operate for the study, 17 had mild fibrosis range, 
3 had moderate fibrosis range and 14 had cirrhotic range. 
 
ROUTES OF LIVER BIOPSY:  
 
Figure 13: Graph showing the frequency of the various routes of liver biopsy. 
 
Majority of the patient‟s i.e 26 had Transjugular liver biopsy, 9 had ultrasound guided and 4 
had percutaneous blind liver biopsy.  
 
TIME INTERVAL BETWEEEN ARFI AND LIVER BIOPSY: 
Of the 39 patients, 32 (82%) had recent biopsy (less than 1 week from the ARFI elastography 
study) and 7 patients (18%) had liver biopsy in the past ranging from 1 to13 years. Among 
the NCPF group, 5 patients had recent biopsy and 6 patients had biopsy in the past, between 4 
to 13 years. 
 
GRADES OF LIVER FIBROSIS ON HISTOPATHOLOGY: 
 
Of the 39 patients who underwent liver biopsy, 3 patients (7.7%) had no evidence of fibrosis 
(F0), 19 patients (48.7%) had mild fibrosis (F1), 3 patients (7.7%) had moderate fibrosis (F2-
3) and 14 patients (35.9%) had cirrhosis (F4) on histopathology. In this study, 17 patients 
(43.6%) had significant fibrosis i.e greater than or equal to F2.  
 
Figure 14: Graph showing the frequency various grade of liver fibrosis on histopathology. 
 
 HEPATIC VENOUS PRESSURE GRADIENT (HVPG) MEASUREMENTS:  
 
 
18 patients had HVPG measurements taken during the liver biopsy. Out of the 18 patients, 11 
patients had clinically significant portal hypertension (HVPG greater than or equal to 10 mm 
of Hg). The mean HVPG value was 10.33 mm of Hg with a range from 1-23 mm of Hg.  
Majority of the patients had catheter wedge method of HVPG measurement. 
 
GRADING OF ESOPHAGEAL VARICES ON ENDOSCOPY: 
 
 
 
Figure 16: Graph showing the frequency grades of esophageal varices on endoscopy among 
liver biopsy patients. 
 
 
Of the 39 patients, 28 patients underwent endoscopy for evaluation of esophageal varices. 6 
(15.4%) patients had large esophageal varices representing clinically significant portal 
hypertension. Of the 39 patients, 12 (30.8%) had prior endoscopic variceal ligation (EVL).  
Among the 6 patients with large esophageal varices, 2 had prior EVL. 
 
1. DIAGNOSTIC ACCURACY OF ARFI ELASTOGRAPHY OF LIVER AND 
SPLEEN TO IDENTIFY NONCIRRHOTIC PORTAL FIBROSIS (NCPF) FROM 
CIRRHOSIS WITH PORTAL HYPERTENSION: 
Among the 39 cases with a preliminary diagnosis of cryptogenic cirrhosis that underwent 
liver biopsy, 11 were biopsy proven cases of NCPF and 28 causes of liver cirrhosis due to 
other causes with portal hypertension. 
The mean age of the NCPF group was 34 years with male: female sex ratio of 7:4. The 
average platelet count was 69,000. Most NCPF patients had normal liver functions.   
 
 NCPF 
GROUP 
 
 
LIVER 
CIRRHOSIS 
GROUP 
Number of 
cases 
11 28 
Gender (M:F) 7:4 15:13  
Age * yrs 34 36 
Platelet count * 
 
69,000 90,000 
AST*  38 51 
ALT 23.5 36 
Total bilirubin* 1.4 2.1 
Albumin* 4.1 3.6 
PT-INR* 1.1 1.18 
Esophageal 
varices 
8 13 
EVL 3 7 
Ascites 
Absence  
10 17 
 
Table 6: Comparison of the demographic, biochemical and clinical parameters of NCPF and 
liver cirrhosis group.*Median value, AST- Aspartate aminotransferase, ALT- Alanine 
aminotransferase, PT- INR- Prothrombin time with international normalized ratio, EVL- 
endoscopic variceal ligation in the past.  
There is only one published study in literature recently from Japan which has studied the use 
of ARFI elastography of the liver and spleen to identify NCPF (25). No Indian studies have 
been published. The cut-off values suggested by the Japanese study were liver stiffness (LS) 
< 1.65 cm/sec, spleen stiffness (SS) > 2.69 cm / sec and ratio of SS and LS (SS/LS) > 1.53 to 
identify NCPF from other causes of liver cirrhosis (25). 
 
In the present study, NCPF group 45.5% (n=5) had LS < 1.65 cm/ sec and 54.5 %( n=6) had 
LS > 1.65 cm/ sec, 70% (n=7) had SS > 2.72 cm / sec and 63% (n=7) had SS/LS > 1.53 
cm/sec.  
In the liver cirrhosis group, 21.4% (n=6) had LS< 1.65 cm/ sec and 71.4% (n=20) had LS > 
1.87 cm / sec i.e in the cirrhotic velocity range. 79 % (n=19) had SS >2.72 cm/sec and 25% 
(n=5) had SS/LS > 1.53 cm/ sec. 
 
ARFI ELASTOGRAPHY 
CUT-OFF 
NCPF GROUP 
 (n=11) 
LIVER CIRRHOSIS GROUP 
(n=28) 
LS < 1.65 cm/ sec 45.5% (n=5) 21.4% (n=6) 
SS > 2.69 cm / sec 70% (n=7) 79 % (n=19) 
SS/LS > 1.53 cm/ sec 63% (n=7) 25% (n=5) 
EITHER LS or SS or SS/LS  90% (n=10) 78% (n=22) 
Table 7: Table showing the percentages and the frequency of cases among NCPF and liver 
cirrhosis group according to the cut-off described in the Japanese study. 
 
In the present study, the median LS, SS and SS/ LS velocities in NCPF group were 1.75 cm/ 
sec, 3.11 cm/sec and 1.81 cm/ sec respectively. The median LS, SS, SS/ LS in the cirrhosis 
group were 2.5 cm/ sec, 2.53 cm/ sec and 1.22 cm/ sec respectively. 
 NCPF  
 
LIVER 
CIRRHOSIS 
Median LS  
 
1.75 2.5 
Median SS 
 
3.11 2.95 
Median SS/ LS 
 
1.81 1.23 
Table 8: Median ARFI elastography velocities of liver stiffness (LS), spleen stiffness (SS) 
and the ratio of spleen stiffness to liver stiffness (SS/LS) in NCPF and liver cirrhosis group. 
Median velocities in cm/sec. 
 
Each liver biopsy patient was coded as test positive by ARFI elastography for LS, SS, and 
SS/LS according to the cut off values which are mentioned in the literature. The sensitivity, 
specificity, PPV, NPV and likelihood ratios were calculated. 
COMBINATION OF 
EITHER LS*, SS* 
AND SS/LS* 
NCPF 
 
LIVER 
CIRRHOSIS 
TEST POSITIVE 
BY ARFI  
10 22 
TEST NEGATIVE 
BY ARFI 
1 6 
TOTAL CASES 11 28 
Table 9: Two by two table showing the number of biopsy proven NCPF and liver cirrhosis 
that were positive for LS, SS, and SS/LS cut off values by ARFI elastography. * Liver 
stiffness (LS), spleen stiffness (SS) and the ratio of spleen stiffness to liver stiffness (SS/LS). 
 
ARFI elastography of the liver (LS) had 36 % sensitivity, 93% specificity, PPV of 90%, NPV 
of 78.8 % and kappa of 0.28 and p value of 0.04 to identify NCPF from other liver cirrhosis 
which was statistically significant.  
Spleen stiffness (SS) had 70% sensitivity, 20% specificity, PPV of 26.9% and NPV of 62.5%, 
kappa of -0.63 and p value of 0.5 which was not statistically significant.  The SS/ LS ratio 
had 70% sensitivity, 79.2% specificity, PPV of 58.3%, NPV of 86.4% with kappa of 0.46 and 
p value of 0.06 which was statistically not significant. The kappa agreement with the liver 
biopsy for LS, SS, and SS/LS was low. 
 
 The combination of either LS, SS or SS/ LS had sensitivity of 82%, specificity of 21.4%, 
PPV of 29%, NPV of 75% and kappa of 0.02 (p=0.8). 
 
ARFI  
VARIABLES  
SENSITIVITY SPECIFICITY PPV NPV 
LS* 36% 93% 90% 44.8 % 
SS* 70% 20.8% 26.9% 62.5% 
SS/LS* 70% 79.2% 58.3% 86.4% 
COMBINATION  
OF LS, SS AND 
SS/LS  
82 % 21.4% 29% 75% 
Table 10: Comparison of LS, SS and SS/LS and the combination of either of these parameters 
to identify NCPF from other causes of cirrhosis with portal hypertension.*LS- Liver stiffness, 
SS- spleen stiffness, SS/LS ratio- Spleen stiffness / Liver stiffness.  
 
Among the NCPF group, Spearman correlation (rho) for LS with liver biopsy was 0.3 
(p=0.31) and for SS with liver biopsy was -0.28 with p=0.5 which were statistically not 
significant.  
 
Among the liver cirrhosis group, Spearman correlation (rho) for LS with liver biopsy among 
was 0.57 (p=0.01) which was statistically significant. Spearman correlation (rho) of SS with 
liver biopsy was -0.15 (p=0.4) which was statistically not significant. 
 
Among the 9 patients who were clinically suspected to have NCPF but did not undergo liver 
biopsy, 6 (66.67%) had LS < 1.65 cm/ sec, 6 (66.67%) had SS > 2.69 cm/ sec and 6 (66.67%) 
had SS/LS >1.53 cm/ sec which are suggestive of NCPF on ARFI elastography.  
 
The best individual ARFI elastography parameter to identify NCPF from other causes of 
cirrhosis was found to be the ratio of spleen stiffness to liver stiffness (SS/LS) with good 
sensitivity, specificity, negative predictive value and good kappa correlation. The 
combination of LS, SS or SS/LS had the maximum sensitivity but had low specificity. 
 
 
 
 
 
 
 
 
 
2. DIAGNOSTIC ACCURACY ARFI ELASTOGRAPHY OF LIVER AND SPLEEN 
TO DIFFRENTIATE SIGNIFICANT LIVER FIBROSIS FROM NON-SIGNIFICANT 
LIVER FIBROSIS:  
LIVER BIOPSY LS SS LS x SS SS/ LS 
NOT SIGNIFICANT N  22 17 17 17 
Mean 1.8614 3.0206 6.1359 1.70276 
Median 1.7250 2.9200 5.2900 1.52000 
Std. Deviation .74484 .41814 2.57121 .689253 
Minimum 1.00 2.47 3.08 .860 
Maximum 3.50 3.82 11.41 3.080 
SIGNIFICANT N  17 17 17 17 
Mean 2.6212 3.0482 7.9841 1.23571 
Median 2.5900 3.1200 7.9800 1.21000 
Std. Deviation .65018 .34877 2.28189 .370352 
Minimum 1.54 2.35 4.31 .660 
Maximum 3.73 3.72 13.35 2.040 
Table 11: Mean and Median velocities of liver stiffness (LS), spleen stiffness (SS), LS x SS 
and SS/LS measurements with standard deviation and shear wave velocity ranges to 
differentiate significant liver fibrosis from non-significant liver fibrosis. 
 
Based on the prior published literature the liver stiffness (LS) velocity cut-off value of 1.35 
cm/ sec, was taken to differentiate significant fibrosis from non-significant fibrosis (18).  
 
LS was found to have 100 % sensitive to identify significant liver fibrosis (>F2), but has a 
low specificity of 30.4%. The positive predictive value (PPV) was 45.2 % and negative 
predictive value was 100% with kappa of 0.33, (p=0.05) and Likelihood ratio of 1.57.   
The spleen stiffness cut-off value of 2.51 cm/ sec was taken to differentiate cirrhosis from 
lesser grades of liver fibrosis (30). ARFI elastography of spleen was found to have 100% 
sensitivity, 10% specificity, PPV of 43.7%, NPV of 100% and kappa of 0.08 to identify liver 
cirrhosis.   
 
The ratio of spleen stiffness (SS) to liver stiffness (LS) cut off value of 1.53 cm/ sec was 
taken to differentiate significant fibrosis from non significant fibrosis. ARFI elastography 
measurements of SS/ LS were found to have 76.5% sensitivity, 47% specificity, PPV of 59%, 
NPV of 66.7% and kappa of 0.23 (P= 0.1) The best parameter to identify significant fibrosis 
was the combination of both liver and spleen elastography i.e SS/ LS ratio.  
 
Both the liver stiffness and spleen stiffness measured by ARFI elastography have 100 % 
sensitivity to identify significant fibrosis but have low specificity. They have 100 % NPV and 
low PPV. The combination of SS/ LS was found to have higher specificity of 47% and 76.5% 
specificity. The p value of LS was 0.002, SS was 0.68, LS x SS was 0.034 and SS/ LS was 
0.049. The liver stiffness (LS), product of LS and SS and ratio of SS/ LS were found to 
statistically significant differentiate between significant from non-significant liver fibrosis. 
The spleen stiffness was not found to be useful to identify significant liver fibrosis. 
 
 
 
 
 
 
ARFI ARFI  SENSITIVITY SPECIFICITY PPV NPV Kappa  P value 
LS* <1.35 100 % 30.4% 45.2% 100% 0.3 0.002 
SS* >2.51 100% 10% 43.7% 100% 0.08 0.68 
SS/LS* >1.53 76.5% 47% 59% 66.7% 0.23 0.049 
Table 12: Comparison of LS, SS and SS/LS to differentiate significant liver fibrosis from 
non-significant liver fibrosis.*LS- Liver stiffness, SS- spleen stiffness, SS/LS ratio- Spleen 
stiffness / Liver stiffness. Column 2 indicates the ARFI cut off values in cm/ sec. 
 
 
 
 
 
 
 
Table 13: Mann- Whitney U test for liver stiffness (LS), spleen stiffness (SS), product of LS 
and SS and SS/ LS to differentiate between significant liver fibrosis from non-significant 
liver fibrosis. 
 
 
 
 LS SS LS x SS SS/ LS 
Mann-Whitney U 82.500 132.000 83.000 87.500 
Wilcoxon W 335.500 285.000 236.000 240.500 
Z -2.960 -.431 -2.118 -1.964 
Asymp. Sig. (2-tailed) .003 .667 .034 .050 
                P value .002 .683 .034 .049 
DIAGNOSTIC ACCURACY OF ARFI ELASTOGRAPHY OF THE LIVER TO 
IDENTIFY GRADES OF LIVER FIBROSIS ON BIOPSY: 
 
The liver stiffness (LS) velocity measurements were correlated with the grades of liver 
fibrosis on biopsy.  The ARFI liver stiffness velocity cut-off for mild fibrosis (F0-F1) was 
taken as < 1.34 cm/ sec, moderate fibrosis (F2-3) as 1.35-1.86 cm/ sec and greater than 1.87 
cm/ sec for cirrhosis (F4) (18). 
There were 19 patients who had mild fibrosis (48.7%), 3 with moderate fibrosis (7.7%) and 
14 with cirrhosis (35.9%).  Of the 19 patients with mild fibrosis, only 6 patients (31.6%) were 
accurately identified as mid fibrosis by ARFI elastography and 13 patients (69.3%) had 
velocities greater than 1.35 cm/ sec. Of the 3 patients with moderate fibrosis on biopsy, 1 
(33.3%) patient had LS velocity in the moderate fibrosis range and 2 (66.7%) had velocities 
in cirrhotic range. Of the 39 patients with cirrhosis on biopsy, 25 (64.1%) had LS velocities 
in the cirrhotic range, 6 (15.4%) in the moderate fibrosis range and 8 (20.5%) had velocities 
in the mild fibrosis range.  
The sensitivity of ARFI elastography to identify no fibrosis was 66.7%, 31.6% for mild 
fibrosis, 33.3% for moderate fibrosis and 64.1% for cirrhosis. 
Spearman correlation (rho) of the liver stiffness (LS) with the fibrosis grades on liver biopsy 
was 0.54 with p value of < 0.001 which was statistically significant. This states that as the 
liver fibrosis increases the liver stiffness velocity also increases. 
The liver stiffness measurement by ARFI elastography has higher sensitivity to identify 
moderate fibrosis and cirrhosis and low sensitivity to identify mild fibrosis. 
 
 ARFI LIVER 
STIFFNESS (LS)  
VELOCITY  
(cm/ sec) 
LIVER BIOPSY GRADE 
 
NIL 
 (F0) 
    MILD  
     (F1) 
 MODERATE 
      (F2-3) 
 
CIRRHOSIS 
     (F4) 
  <1.35   2 6 0 8 
 66.7% 31.6% .0% 20.5% 
1.35-1.86  1 3 1 6 
 33.3% 15.8% 33.3% 15.4% 
>1.87  0 10 2 25 
 .0% 52.6% 66.7% 64.1% 
                      
TOTAL 
 3 19 3 39 
 100.0% 100.0% 100.0% 100% 
 
Table 14: Comparison of liver stiffness (LS) velocities by ARFI elastography with grades of 
fibrosis on liver biopsy. 
 
 
 
 
 
3A. DIAGNOSTIC ACCURACY OF ARFI ELASTOGRAPHY OF LIVER AND 
SPLEEN TO IDENTIFY CLINICALLY SIGNIFICANT PORTAL HYPERTENSION 
AS COMPARED TO HEPATIC VENOUS PRESSURE GRADIENT (HVPG): 
Clinically significant portal hypertension is defined as HVPG > 10 mm of Hg.  ARFI 
elastography liver stiffness cut off of > 1.67 cm / sec and spleen stiffness cut off value of   
>3.3 cm / sec were taken to identify clinically significant portal hypertension (31). 
 Total 18 patients who underwent liver biopsy had HVPG measurements. Among the NCPF 
group, 8 patients had HVPG measurements, 37.5% (n=3) had HVPG > 10 mm Hg. With LS, 
one case (33%) among the 3 was identified to have HVPG > 10 mm of Hg and with SS 2 
(66.7%) out of 3 cases had CSPH. In the liver cirrhosis group, 10 patients had HVPG 
measurements, 40% (n=4) had HVPG > 10 mm of Hg.  Using LS, 2 out of 4 cases were 
identified and using SS none were identified. 
VARIABLE ARFI  
cm/ sec 
SENSITIVITY SPECIFICITY PPV NPV KAPPA 
LS* >1.67 57% 27% 33% 50% -0.01 
SS* >3.3 14.3% 90% 50% 60% 0.04 
Table 15: Comparison of LS and SS velocities to identify clinically significant portal 
hypertension as compared to HVPG. *LS- Liver stiffness; SS- Spleen stiffness. Column 2 
indicates the ARFI cut off values in cm/sec. 
Liver stiffness (LS) was found to have 57% sensitivity, 27% specificity, PPV of 33%, NPV 
of 50% and kappa of -0.13 (p=0.49) and Spleen stiffness(SS) was found to have 14.3% 
sensitivity, 90% specificity, PPV of 50%, NPV of  60% and kappa of 0.04, (p-0.78). Both LS 
and SS were found to have low sensitivity with low kappa agreement and were statistically 
not significant to identify clinically significant portal hypertension as compared to HVPG. 
 
3B. DIAGNOSTIC ACCURACY OF ARFI ELASTOGRAPHY OF LIVER AND 
SPLEEN TO IDENTIFY CLINICALLY SIGNIFICANT PORTAL HYPERTENSION 
AS COMPARED TO HIGH RISK ESOPHAGEAL VARICES ON ENDOSCOPY: 
58 cases of portal hypertension of any etiology were studied to assess the correlation of ARFI 
elastography of the liver and the spleen with the presence of high risk esophageal varices on 
endoscopy. 51 patients had recent endoscopy out of which 13 (25.4%) had high risk 
esophageal varices. This group includes 39 liver biopsy cases, 19 causes of portal 
hypertension without liver biopsy, among which 9 were suspected NCPF cases and 10 cases 
had known etiologies for portal hypertension. 
ARFI elastography liver stiffness cut off of > 1.67 cm / sec and spleen stiffness cut off value 
of > 3.3 cm / sec was taken which was found to represents high risk esophageal varices on 
endoscopy to identify clinically significant portal hypertension (31).  
In the NCPF group, 8 of the 11 patients had esophageal varices on endoscopy, 2 (25%) had 
high risk esophageal varices. Both the patients (100 %) with high risk esophageal varices 
were identified with LS and with SS one (50%) among the 2 cases was identified.   3 patients 
were treated with prior endoscopic variceal ligation.  
In the liver cirrhosis group with liver biopsy, 4 (14%) out of the 28 patients had high risk 
esophageal varices. 2 (50%) were identified using LS and with SS none were identified. 
In the group of third group of patients with portal hypertension, 7 (36%) out of 19 had high 
risk esophageal varices. Only 2(10%) were identified using LS and 3 (42.8%) were identified 
with SS.  
Overall, Liver stiffness (LS) was found to have 46.5% sensitivity, 26.4% specificity, PPV of 
10%, NPV of 56% and  (p= 0.07) which was statistically not significant.  Spleen stiffness was 
found to have 31% sensitivity, 81.25% specificity, PPV of 40%, NPV of 74.3% and  (p=0.38) 
which was statistically not significant. Both LS and SS were found to have low sensitivity 
with low kappa agreement and statistically not significant to identify large esophageal varices 
and clinically significant portal hypertension. 
 
VARIABLE ARFI  SENSITIVITY SPECIFICITY PPV NPV P value 
LS* >1.67  46.5% 26.4% 10 % 56% 0.07 
SS* >3.3 31% 81.25% 40% 74.3% 0.38 
 
Table 16: Comparison of LS and SS velocities to identify clinically significant portal 
hypertension as compared to endoscopy. *LS- Liver stiffness; SS- spleen stiffness. Column 2 
indicates the ARFI cut off values in cm/sec. 
 
                                                     
                                               
 
 
 
 
DISCUSSION: 
Non cirrhotic portal fibrosis (NCPF)/ Non cirrhotic intrahepatic portal hypertension (NCIPH) 
or idiopathic portal hypertension (IPH) is a rare disease of unknown etiology characterized by 
portal hypertension and splenomegaly. They can present with esophageal varices, portal 
hypertensive gastropathy, liver function disorders, anaemia, ascites and encephalopathy but 
does not lead to cirrhosis or hepatocellular carcinoma. On routine imaging, NCPF can mimic 
cryptogenic cirrhosis and hence can be misdiagnosed.  Liver biopsy is essential for the 
diagnosis. The importance of making accurate diagnosis of NCPF is that these patients have 
excellent prognosis when treated adequately for portal hypertension.  
ARFI elastography is a novel ultrasound based technology which is combined with B-mode 
ultrasound. It quantifies the stiffness of the tissues by using acoustic push pulses and 
measures the shear wave velocities in the tissues which are proportional to the degree of 
stiffness of the target organ. ARFI is superior to transient elastography which is based on A- 
mode imaging and requires higher skill for the examiners. 
NCPF is termed as “obliterative portal sclerosis” as there is portal sclerosis in and thin 
fibrous septa in the absence of cirrhosis on histopathology. The occlusion of peripheral portal 
veins in the liver causes increase in blood flow to the spleen, causing pulp hyperplasia, 
congestion from increased blood flow and  fibrosis within the spleen resulting in  
splenomegaly and portal hypertension. 
There is only one study published in literature from Japan by Furuichi et al. (25) who studied 
the use of ARFI elastography of liver and spleen in NCPF and as compared to liver biopsy.  
The study included 17 NCPF patients, 25 liver cirrhosis, 20 chronic hepatitis and 20 normal 
controls. In the present study, 39 cases underwent liver biopsy with a preliminary diagnosis 
of cryptogenic cirrhosis, out of which 11 had NCPF and 28 had cirrhosis of other causes after 
liver biopsy that were the controls.  
 NCPF/ IPH 
 
 
JAPANESE 
STUDY 
NCPF 
 
 
PRESENT 
STUDY 
LIVER 
CIRRHOSIS 
 
JAPANESE 
STUDY 
LIVER 
CIRRHOSIS 
 
PRESENT 
STUDY 
Number of 
cases 
17 11 25 28 
Gender (M:F) 11:6 7:4 18:7 15:13  
Age * yrs 40 34 71 36 
Platelet count * 
 
86,000 69,000 98,000 90,000 
AST*  27.5 38 42 51 
ALT 17.5 23.5 29 36 
Total 
bilirubin* 
1.15 1.4 1.02 2.1 
Albumin* 4.1 4.1 3.6 3.6 
PT-INR* 1.06 1.1 1.1 1.18 
Esophageal 
varices 
12 8 18 13 
EVL 6 3 7 7 
Ascites 
Absence  
17 10 25 17 
Table 17: Summary of the demographic, clinical and biochemical parameters of the present 
study as compared to the Japanese study. *Median value. 
The mean age in the present study among NCPF group was 34 years as compared to the 40 
years in the Japanese study. The liver function tests were almost similar, except the AST 
levels in the present study were slightly higher, median value being 38 IU/L.  8 of the 11 
patients had esophageal varices on endoscopy and 3 had been treated with endoscopic 
variceal ligation. The patients demographic, clinical and biochemical parameters have been 
compared with the Japanese study summarized in table 16. 
In NCPF, the fibrogenesis enlargement of the spleen causes passive congestion which is 
probably the cause of increase in spleen stiffness.  The increase in liver stiffness in NCPF is 
due to the small amount of peripheral periportal fibrosis. Seijo et al. studied the use of 
transient elastography in IPH and compared to hepatic venous pressure gradient (HVPG) 
(27). They reported that the liver stiffness in IPH is lower than the liver cirrhosis. Thus, 
NCPF/ IPH is a disease with soft liver and hard spleen and hence the spleen/ liver stiffness 
ratio is increased (25).  
In the present study, the liver stiffness (LS), spleen stiffness (SS) and SS/ LS ratio cut-offs 
were taken from the Japanese study (28).  The median liver stiffness (LS) was 1.75 cm/ sec 
which was higher than the Japanese study. The increase in the liver stiffness is probably due 
to the fact that some NCPF cases were diagnosed few years earlier and had increase in 
peripheral periportal liver fibrosis as compared to the newly diagnosed cases. Among the 
liver cirrhosis group, the median liver stiffness was comparable with the Japanese study. 
 
 NCPF/ IPH  
 
 
JAPANESE 
STUDY 
NCPF  
 
 
PRESENT 
STUDY 
LIVER 
CIRRHOSIS 
 
JAPANESE 
STUDY 
LIVER 
CIRRHOSIS 
 
PRESENT 
STUDY 
Median LS  1.56 1.75 2.44 2.5 
Median SS 
 
3.88 3.11 3.18 2.95 
Median SS/ LS 
 
2.47 1.81 1.3 1.23 
Table 18: Comparison between the liver stiffness (LS), spleen stiffness (SS) and SS/LS ratio 
among NCPF and cirrhosis group in the present study and the Japanese study. Median 
velocities in cm/sec. 
The sensitivity of liver stiffness in the present study to identify NCPF was 36% as compared 
to 65% in the Japanese study. However the specificity of 93%and the positive predictive 
value (PPV) of 90 % are comparable with the prior study. This indicates that assessment of 
liver by itself in NCPF is not adequate to identify NCPF from cirrhosis. However as the 
specificity is 93%, if the liver stiffness velocity is elevated i.e greater than 1.65 cm/ sec, the 
probability of the patient having NCPF is very low. 
LIVER  
STIFFNESS 
(SS) 
NCPF/ IPH  
 
JAPANESE 
STUDY 
NCPF  
 
PRESENT 
STUDY 
Sensitivity 
  
65 %  36 % 
Specificity 92%  93% 
PPV 85%  90% 
NPV 79 %  48% 
Table 19: Comparison of the sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) of liver stiffness (LS) between the Japanese study and the 
present study. 
The spleen area (product of the maximum length into shortest diameter) of the present study 
and the Japanese study are similar in the NPCF group. The median spleen stiffness (SS) 
velocity in the present study was 3.11 cm/ sec which was lower than the Japanese study of 
3.88 cm/ sec. The correlation of the spleen area with the spleen stiffness in this study was not 
found to be statically significant which was also reported by the Japanese study. This 
suggests that the spleen size may not reflect the extent of spleen fibrosis and degree of portal 
hypertension. The sensitivity and specificity of spleen stiffness to identify NCPF in this study 
were found to 70 % sensitivity and 21 % specificity as compared with 100 % and 95% in the 
Japanese study.  This may due to the lower sample size in this study and also due to the lack 
of any Indian studies for comparison. More studies are required to further study the cause for 
lower splenic stiffness in Indian population.  
 NCPF/ IPH  
 
JAPANESE 
STUDY 
NCPF  
 
PRESENT 
STUDY 
LIVER 
CIRRHOSIS 
JAPANESE 
STUDY 
LIVER 
CIRRHOSIS 
PRESENT 
STUDY 
Spleen area 
cm 2 
102.5  101.6 44 102.5 
Spleen stiffness 
  cm/ sec 
3.88 3.11 3.18 2.95 
Table 20: Comparison between the spleen area and splenic stiffness in the present study and 
the Japanese study. 
SPLEEN 
STIFFNESS 
(SS) 
NCPF/ IPH  
 
 
JAPANESE 
STUDY 
NCPF  
 
 
PRESENT 
STUDY 
Sensitivity 
  
100 % 70% 
Specificity 95% 21% 
PPV 94 % 27% 
NPV 100 % 62.5% 
Table 21: Comparison of the sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) of spleen stiffness (SS) between the Japanese study and the 
present study. 
Among the NCPF group, Spearman correlation (rho) for LS with liver biopsy was 0.3 and 
p=0.31 which was statistically not significant. Spearman correlation of SS with liver biopsy 
was -0.28 with p=0.5 which was statistically not significant. This may be due to the low 
sample size. 
 
The spleen to liver stiffness ratio (SS/LS) had 70%, sensitivity, 79% specificity, PPV of 
58.3% and NPV of 86.4%. The sensitivity in this study was lower than the Japanese study, 
however the specificity was higher. The combination of either LS, SS or SS/ LS had 
sensitivity of 82%, specificity of 21.4 %, PPV of 29%, NPV of 75%, kappa of 0.02 (p=0.8) to 
identify NCPF from other liver cirrhosis. The best individual parameter of ARFI elastography 
to identify NCPF from other causes of cirrhosis was found to be the ratio of spleen stiffness 
to liver stiffness (SS/LS) with good sensitivity, specificity, negative predictive value and 
good kappa correlation which was also found to be the best parameter in the Japanese study.  
SS/ LS NCPF/ IPH  
 
 
JAPANESE 
STUDY 
NCPF  
 
 
PRESENT 
STUDY 
Sensitivity 
  
100 % 70%  
Specificity 72% 79.2%  
PPV 71% 58.3%  
NPV 100 % 86.4 %  
Table 22: Comparison of the sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) of spleen stiffness to liver stiffness ratio (SS/ LS) between 
the Japanese study and the present study. 
Hence ARFI elastography of the liver and the spleen in combination have good sensitivity 
and can be used as screening tool for non invasive detection on NCPF patients from other 
causes of liver cirrhosis. Currently liver biopsy is required for accurate diagnosis. Larger 
multicentric studies among Indian population are required as none are available at present. In 
future ARFI elastography of the liver and spleen can be used as of the diagnostic criterion for 
non- invasively diagnosis of NCPF patients. 
DIAGNOSTIC ACCURACY ARFI ELASTOGRAPHY OF LIVER AND SPLEEN TO 
DIFFRENTIATE SIGNIFICANT LIVER FIBROSIS FROM NON SIGNIFICANT 
LIVER FIBROSIS: 
 
According to a large meta-analysis by Nierhoff et al, the ARFI shear wave velocity cut-off 
values of liver are 1.35 m/s for the diagnosis of significant fibrosis, 1.61 m/s for the diagnosis 
of severe fibrosis and 1.87 m/s for the diagnosis of liver cirrhosis. The mean diagnostic 
accuracy of ARFI of the liver expressed as the AUROC was 0.84 (DOR, 11.54) for the 
diagnosis of significant fibrosis (F ≥ 2), 0.89 (DOR, 33.54) for the diagnosis of severe fibrosis 
(F ≥ 3) and 0.91 (DOR, 45.35) for the diagnosis of liver cirrhosis (F = 4). The meta-analysis 
revealed good diagnostic accuracy of the ARFI elastography of the liver for the staging of 
F ≥ 2 and F ≥ 3, and excellent diagnostic accuracy for F = 4 (21).  
 
In the present study, LS was found to have 100 % sensitive to identify significant liver 
fibrosis (>F2), but has a low specificity of 30.4%. The positive predictive value (PPV) was 
45.2 % and negative predictive value was 100% with kappa of 0.33, (p=0.05) and Likelihood 
ratio of 1.57 which was statistically significant. Thus the use of ARFI in identifying 
significant liver fibrosis in this study is comparable to the already published studies. 
 
 ARFI elastography of spleen was found to have 100% sensitivity, 10% specificity, PPV of 
43.7%, NPV of 100% and kappa of 0.08 to identify liver cirrhosis. The spleen stiffness was 
not found to statistically significant to identify significant liver fibrosis.  
 
The ratio of spleen stiffness (SS) to liver stiffness (LS) cut off value of 1.53 cm/ sec was 
taken to differentiate significant fibrosis from non significant fibrosis. ARFI elastography 
measurements of SS/ LS was found to have 76.5% sensitivity, 47% specificity, PPV of 59%, 
NPV of 66.7% and kappa of 0.23 (P= 0.1) The best parameter to identify significant fibrosis 
was the combination of both liver and spleen elastography i.e SS/ LS ratio. The liver stiffness 
(LS), product of LS and SS and ratio of SS/ LS were found to statistically significant 
differentiate between significant from non significant liver fibrosis.  
 
The sensitivity of ARFI elastography to identify no fibrosis was 66.7%, 31.6% for mild 
fibrosis, 33.3% for moderate fibrosis and 64.1% for cirrhosis. The liver stiffness 
measurement by ARFI elastography had higher sensitivity to identify moderate fibrosis and 
cirrhosis, and low sensitivity to identify mild fibrosis.  The sensitivity and specificity in this 
study may be low due to the smaller sample size. 
Ye et al. found significant linear correlation (Spearman ρ = 0.87; P < .001) between liver 
stiffness and the fibrosis stage (29).  In the present study Spearman correlation of the liver 
stiffness (LS) with the grades of fibrosis on liver biopsy was ρ =0.54 with p value of < 0.001 
which was statistically significant. This states that as the liver fibrosis increases the liver 
stiffness velocity also increases which is similar to the studies published in literature. 
 
 
 
 
 
 
 
 
DIAGNOSTIC ACCURACY OF ARFI ELASTOGRAPHY OF LIVER AND SPLEEN 
TO IDENTIFY CLINICALLY SIGNIFICANT PORTAL HYPERTENSION AS 
COMPARED TO HEPATIC VENOUS PRESSURE GRADIENT (HVPG) AND HIGH 
RISK VARICES ON ENDOSCOPY: 
 
Rifai et al. studied 125 patients and found that splenic stiffness is better than liver stiffness to 
predict significant portal hypertension (AUORC 0.90 vs 0.68). The cut-off used was > 1.67 
cm/ sec for LS (26).  Rifai et al. also found that spleen stiffness is not useful to predict portal 
hypertension. The SS cut-off value for predicting portal hypertension was 3.29 m/s, with 47% 
sensitivity and 73% specificity (63).  
In the present study, liver stiffness (LS) was found to have 57% sensitivity, 27% specificity, 
PPV of 33%, NPV of 50% and kappa of -0.13 (p=0.49) and Spleen stiffness(SS) was found to 
have 14.3% sensitivity, 90% specificity, PPV of 50%, NPV of  60% and kappa of 0.04, (p-
0.78) . Both LS and SS were found to have low sensitivity with low kappa agreement and 
were statistically not significant to identify clinically significant portal hypertension as 
compared to HVPG. This may be due to the fact that the number of patients who underwent 
HVPG measurements was small. 
 
There are very few studies which analysed the use of liver and spleen stiffness to identify 
significant esophageal varices. Vermehren et al. found that ARFI of spleen is better than 
ARFI of the liver for esophageal varices (63). Study done by Ye et al. showed that liver 
stiffness did not correlate with the grade of esophageal varices (29).  Takuma et al, found that 
SS had the greatest diagnostic accuracy for the identification of patients with high-risk 
esophageal varices, as compared to liver stiffness and other non-invasive parameters and is 
independent of the etiology of cirrhosis. SS cut-off value of 3.30 m/s had 99.4% negative 
predictive value, 98.9% sensitivity, 72.1% accuracy, and 0.018 negative likelihood ratio. SS 
values less than 3.3 m/s ruled out the presence of high-risk varices in patients with 
compensated or decompensated cirrhosis (31). Singh et al. a systematic review and meta-
analysis  of 9 studies, SS detected the presence of clinically significant esophageal varices  
with 81% sensitivity, 66% specificity, a positive LR of 2.5, a negative LR of 0.2, and a 
diagnostic odds ratio of 12.6. Due to the different elastography techniques and study 
locations there was significant heterogeneity among the studies. They proposed that the 
current techniques of measuring splenic stiffness are limited to detect esophageal varices 
(32). 
In this study, liver stiffness (LS) was found to have 46.5% sensitivity, 26.4% specificity, PPV 
of 10%, NPV of 56% and  (p= 0.07) which was statistically not significant.  Spleen stiffness 
was found to have 31% sensitivity, 81.25% specificity, PPV of 40%, NPV of 74.3% and  
(p=0.38) which was statistically not significant. Both LS and SS were found to have low 
sensitivity with low kappa agreement and statistically not significant to identify large 
esophageal varices and clinically significant portal hypertension. Further Indian studies with 
larger sample size are needed to for assessing ARFI elastography of the liver and spleen to 
diagnose esophageal varices. 
                                                     
        
 
 
 
 
 
 
       CONCLUSIONS: 
 
1. ARFI elastography of the liver and the spleen in combination have good sensitivity to 
identify Noncirrhotic portal fibrosis (NCPF) from cirrhosis with portal hypertension 
as compared to liver biopsy. The best elastography parameter was the spleen stiffness 
to liver stiffness ratio.  Liver and spleen stiffness independently are not adequate. 
ARFI elastography can be used a screening tool to non-invasively diagnose and 
monitor patients with NCPF, however lacks good specificity.  
 
2. ARFI elastography of the liver and the spleen stiffness to liver stiffness ratio have 
good sensitivity to identify significant liver fibrosis as compared to liver biopsy. 
There is good correlation with liver stiffness velocities and grades of liver fibrosis. 
ARFI elastography can be used as good screening test to diagnose and monitor 
disease progression in patients with chronic liver disease. 
 
3. ARFI elastography of the liver and spleen have low sensitivity and low specificity to 
identify clinically significant portal hypertension as compared to hepatic venous 
pressure gradient (HVPG) measurements and the presence of high risk esophageal 
varices on endoscopy. 
 
 
 
 
 
 
                                               
       LIMITATIONS: 
 
• NCPF is an uncommon disease. The number of biopsy proven cases of NCPF 
recruited in this study is small (n=11). Further case recruitment is on-going.  
• Only one published study in literature from Japan, no Indian data for comparison. 
• ROC curves could not be drawn as the areas under the ROC curve was low due to low 
sample size. Hence cut-off velocities were taken from the already published studies. 
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APPENDIX 1: CLINICAL RESEARCH FROM. 
 
Study number: 
 
Name:  
Age:  
Gender: 
Hospital number: 
Address: 
Contact number: 
Height: 
Weight: 
BMI: 
 
Clinical Parameters: 
Asymptomatic:                               
Jaundice:                                         
Ascites:                                             
Past history of upper GI bleed:    
Others:   
CHILD PUGH‟S score: 
Any other co-morbid illness: 
 
Blood Parameters: 
Haemoglobin: 
WBC count: 
Platelet count: 
Prothrombin time: 
Serum total bilirubin: 
Serum direct bilirubin: 
Serum total protein: 
Serum albumin: 
AST: 
ALT: 
Alkaline phosphatase: 
PT-INR: 
 
Imaging findings: 
USG: 
Liver size: 
Liver echotexture: 
Volume redistribution: 
Surface irregularity: 
Periportal echogenicity: 
Hepatic veins: 
Portal vein size: 
Portal vein thrombosis: 
Splenic vein size: 
Spleen size: 
Spleen area: 
Collaterals: 
 
ARFI Elastography: 
Liver stiffness median velocity (LS) in m/sec: 
Spleen stiffness median velocity (SS) in m/sec: 
SS/LS 
 
Method of liver biopsy:   
Percutaneous blind biopsy:                    
USG guided liver biopsy:                        
Transjugular liver biopsy (TJLB):             
With TJLB was HVPG done:                     
 
HVPG value: 
Method of HVPG measurement: 
 
 
Gastroscopy report: 
Esophageal varices 
Grade of esophageal varices:              
Any prior procedure: 
Other findings: 
 
 
Liver histopathology report:  
 
                                 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX2:  INFORMED CONSENT 
Department of Radio diagnosis, Christian Medical College, Vellore 
                                                Information sheet 
You are being requested to participate in a study to see if new ultrasound technique called 
acoustic radiation forced impulse (ARFI) elastography ultrasound, which can help in non-
invasively assess the presence of liver fibrosis i.e liver stiffness and also to stage the liver 
disease. Presently the presence and stage of liver fibrosis is best assessed by a liver biopsy. 
By this study, we may be able to assess the liver fibrosis early and would help your treating 
doctor to give appropriate therapy. 
How does ARFI help in assessing of liver and spleen in NCPF? 
We have observed that there is difficulty in identifying the exact cause of your liver problem 
with the routine blood tests. Using ARFI, we study the stiffness of the liver and spleen which 
can tell us the probable cause and the degree of liver involvement. However, we have only 
used this for a few people and we need to use it on more people to be sure that it really helps. 
Does ARFI have any side effects? 
There are no known side-effects. This additional ultrasound scan will take 10 minutes. 
If you take part what will you have to do? 
If you agree to participate in this study, there will be no change in the other treatments and 
investigations that you will be having.  During the scan, you will be asked to hold your breath 
for few times. You will be expected to come for follow up with your doctor after the liver 
biopsy. No additional blood tests will be done as a part of this study. 
 
 
Can you withdraw from this study after it starts? 
Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study. If you do so, this will not affect your usual 
treatment at this hospital in any way.  
What will happen if you develop any study related injury? 
This scan does not involve injections or radiation and it is completely non invasive.  So, we 
do not expect any procedure related injury. However you can immediately report to us. 
Will you have to pay for the ARFI?  
You will not be charged for this additional scan. All other investigations, as requested by 
your doctor will continue in the usual manner. How much you pay for these investigations 
will not change and this has nothing to do with your participation in this study.  
What happens after the study is over? 
You may or may not benefit from this study. Once the study is over, if we come to a 
conclusion that the investigation is beneficial in assessing the presence and stage of liver 
fibrosis, we will be able to use this technique in assessing and prognosticating patients in 
future. Your doctor may also use this on you again on follow up to assess disease progression 
if required. 
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but you will not be identified 
by name in any publication or presentation of results. However, your medical notes may be 
reviewed by people associated with the study, without your additional permission. 
                                                                                                                                                         
          
 CONSENT TO TAKE PART IN THIS STUDY 
 
Study Title:  
Study Number: 
Participant’s name:  
Date of Birth / Age (in years): 
 
I_________________________________, son /daughter of  _____________________________ 
Declare that I have read/been read to the information sheet provided to me regarding this 
study and have clarified any doubts that I had. [  ] 
(Please tick boxes) 
I also understand that my participation in this study is entirely voluntary and that I am free to 
withdraw permission to continue to participate at any time without affecting my usual 
treatment or my legal rights [  ]  
I understand that the study staff and institutional ethics committee members will not need my 
permission to look at my health records even if I withdraw from the trial. I agree to this 
access [  ]  
I agree not to restrict the use of any data or results that arise from this study provided such a 
use is only for scientific purpose(s) [  ] 
I understand that my identity will not be revealed in any information released to third parties 
or published [  ]   
 
I voluntarily agree to take part in this study [  ] 
 
Name: 
Signature/thumb impression 
Date: 
 
Name of witness: 
Relation to participant: 
Date: 
 
